Identification of Sequence Changes in the Cold-Adapted, Live Attenuated Influenza Vaccine Strain, A/Ann Arbor/6/60 (H2N2)

NANCY J. COX,*.1 FUMIO KITAME, † ALAN P. KENDAL, * HUNEIN F. MAASSAB, ‡ AND CLAYTON NAEVE§

*Influenza Branch, Division of Viral Diseases, Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia 30333, †Department of Bacteriology, Yamagata University, School of Medicine, Zao-lida, Yamagata 990-23, Japan, ‡Department of Epidemiology, School of Public Health, The University of Michigan, Ann Arbor, Michigan 48104, §Department of Virology, St. Jude Children's Hospital for Research, 322 N. Lauderdale, Memphis, TN 38101

Received February 29, 1988; accepted August 31, 1988

Nucleotide sequences have been obtained for RNA segments encoding the PB2, PB1, PA, NP, M1, M2, NS1, and NS2 proteins of the influenza A/Ann Arbor/6/60 (H2N2) wild-type (wt) virus and its cold-adapted (ca) derivative that has been used for preparing investigational live attenuated vaccines. Twenty-four nucleotide differences between the ca and wt viruses were detected, of which 11 were deduced to code for amino acid substitutions in the ca virus proteins. One amino acid substitution each was predicted for the PB2, M2, and NS1 proteins. Two amino acid substitutions were predicted for the NP and the PA proteins. Four substitutions were predicted for the PB1 protein. The biological significance of mutations in the PB2, PB1, PA, and M2 genes of the ca virus is suggested by currently available genetic data, a comparison with other available influenza gene sequences, and the nature of the predicted amino acid changes. In addition, the sequence data confirm the close evolutionary relationship between the genomes of influenza A (H2N2) and influenza A (H3N2) viruses.

INTRODUCTION

One approach for producing live attenuated influenza A vaccines is attenuation of new epidemic variants by reassortment with a cold-adapted (ca) temperature-sensitive (ts) mutant donor strain, A/Ann Arbor/6/ 60 (H2N2) (Maassab et al., 1972; Kendal et al., 1981; Cox, 1986). This prototype ca virus was derived by serial passage of the wild-type (wt) A/Ann Arbor/6/60 virus at successively lower temperatures until virus emerged that could replicate efficiently at 25° (Maassab, 1967; Kendal et al., 1981). Although the ca A/Ann Arbor/6/60 donor virus has not been thoroughly tested in human volunteers, it is attenuated in a ferret model system (Maassab et al., 1982). Reassortant viruses that received the hemagglutinin (HA) and neuraminidase (NA) genes from a new H1N1 or H3N2 epidemic variant virus and five or six of their other genes from the ca A/Ann Arbor/6/60 parent have been examined extensively. These ca reassortants had similar ca and ts properties in cell culture, and were attenuated, immunogenic, and phenotypically stable when administered to ferrets (Maassab et al., 1982). They also were attenuated, immunogenic, and protective in challenge and field studies in humans (Davenport et al., 1977; Hrabar et al., 1977; Murphy et al., 1979, 1980, 1981, 1982; Lazar et al., 1980; Reeve et al., 1980b; Mortiz et al., 1980; Van Voorthuizen et al., 1981; Cate and Couch, 1982; Wright *et al.*, 1982; Clements *et al.*, 1983; Belshe and Van Voris, 1984; Couch *et al.*, 1986).

It has not yet been determined if live ca viruses provide the theoretical benefits proposed for attenuated influenza vaccine (Stuart-Harris, 1980) or can be applied for influenza control on a large scale. Promising vaccine trials, however, have justified parallel laboratory studies to examine the molecular basis for attenuation and the genetic stability of the ca A/Ann Arbor/6/ 60 mutant. It was proposed previously that the restricted gene composition of ca reassortant viruses was advantageous for producing live attenuated influenza vaccines because viruses with five or six internal genes of the ca donor strain would be expected to have more uniform biological and attenuation properties (Cox et al., 1979). Genetic stability of several vaccine strains having five or six genes from the ca parent was examined before and after replication in humans using T1 oligonucleotide mapping, and relative genetic stability was demonstrated (Cox and Kendal, 1984). To directly identify genes of the ca donor strain A/Ann Arbor/ 6/60 that contained mutations, we used a variety of biochemical techniques to compare RNAs and proteins of the ca and wt viruses. These procedures detected differences in each of the eight RNA segments of the ca mutant compared with the wt parent (Cox et al., 1986). Here we present the entire nucleotide sequences for the six genes of the wt and ca A/Ann Arbor/6/60 viruses that are relevant for producing reas-

¹ To whom requests for reprints should be addressed.

sortant candidate vaccine viruses. Knowledge of these nucleotide sequences will be useful for monitoring genetic stability of attenuated vaccines during production and use as well as for understanding the molecular mechanism(s) of viral attenuation.

MATERIALS AND METHODS

Viruses and viral RNA

The A/Ann Arbor/6/60 wt virus and the derivation of the ca A/Ann Arbor/6/60 mutant have been described (Maassab, 1967; Kendal et al., 1981). No further plaque purifications or end-point dilutions were performed. Viruses were propagated at a low multiplicity of infection in the allantoic cavity of 10-day-old embryonated eggs at 34° and purified as described previously (Cox and Kendal, 1984). Ca mutant and wt virus preparations used throughout this study for sequencing varied by no more than three egg passages for the mutant (E_4 to E_6) and by five egg passages for the wt (E28 to E32). Sequencing of RNA obtained from these different passage levels of the same virus revealed no sequence differences. Virion RNA was extracted as described previously (Palese and Schulman, 1976) and dissolved to yield approximately 1 mg/ml.

Nucleotide sequence analysis of viral RNA

Sequence analysis was accomplished using either of two variations of the dideoxy chain termination method (Sanger et al., 1977). The incorporative method was performed essentially as described previously (Air, 1979; Cox et al., 1986). Each 5.5-µl reaction mixture contained 45 mM of Tris-HCI (pH 8.3), 45 mM of KCl, 4.5 mM of MgCl₂, 9 mM of DTT, 1.4 μ M of dATP, 12.5 μ Ci of [α -³²P]-dATP (NEN Research Products, Boston, MA),² 45.5 μ M of dGTP (9.1 μ M of dGTP for the G reaction), 4.5 μM of dCTP (9.1 μM of dCTP for the C reaction), 45.5 μM of dTTP (9.1 μM of dTTP for the T reaction), 50-100 ng of RNA, 1-5 ng of primer, 3 units of reverse transcriptase (Life Sciences, Inc., St. Petersburg, FL), and 1–5 μM of ddATP, ddCTP, dd-GTP, or ddTTP. Reaction mixtures were incubated at 37° for 30 min, after which 1 μ l of a chase mixture containing 1 mM each of dATP, dCTP, dGTP, and dTTP was added, and the incubation was continued at 37° for 30 min. Terminal deoxynucleotidyl transferase (Bethesda Research Laboratories, Gaithersburg, MD) was added to the chase mixture when necessary to resolve sequence abiguities (DeBorde et al., 1986). The reaction was stopped by adding 1 μ l of 0.1 *M* EDTA, and samples were dried and finally dissolved in 5 μ l of a formamide dye mixture.

The second method used 5'- γ -³²P-labeled synthetic oligodeoxynucleotides for priming the reaction. Each 5- μ l reaction mixture contained 50 m*M* of Tris–HCl (pH 8.3), 50 m*M* of KCl, 5 m*M* of MgCl₂, 10 m*M* of DTT, 50 m*M* each of dATP, dCTP, dGTP, and dTTP, 3.75 units of human placenta RNase inhibitor (Promega Biotec, Madison, Wl), 200 ng of RNA, 1–5 ng primer, 3 units of reverse transcriptase, and approximately 10 μ *M* of ddATP, ddCTP, ddGTP, or ddTTP. After incubation at 42° for 30 min, reaction products were analyzed on 6 and 8% polyacrylamide gels containing 100 m*M* of Tris–borate (pH 8.3), 5 m*M* of EDTA, and 8.3 *M* of urea.

Oligonucleotide primers were synthesized either by C. W. Naeve (St. Jude Children's Hospital) or by B. Holloway (Centers for Disease Control) on an Applied Biosystems Model 380A DNA synthesizer using the solidphase phosphoramidite method. Primers used were as follows: the universal primer d(AGCAAAAGCAGG), PB2-28 d(ATGGAAAGAATAAAA), PB2-102 d(GGAC-CATATGGC), PB2-225 d(GACAAGAGGATA), PB2-451 d(CGCCGAAGAGTT), PB2-698 d(CAAGCAGTGTAT), PB2-905 d(GGATGGTGGACA) PB2-946 d(GCTGTG-GAAATATGC), PB2-1125 d(TGGGAAAAGGGC), PB2-1349 d(ATGCTAAAGTGC), PB2-1570 d(CCTGAG-GAGGTC), PB2-1780 d(CCTAAGGCCATT), PB2-2085 d(GGAGTCAGCTGT), PB2-2190 d(GGCTAATGTACT), PB1-13 d(CAAACCATTTGAATGG), PB1-208 d(GGAG-CGCCCCAACT), PB1-400 d(CGTCAGACCTATGA), PB1-601 d(GACAACATGACCAAGA), PB1-745 d(AA-TGCAACACCCGGGA), PB1-909 d(CACAGAGCT-TTC), PB1-1000 d(ACAAGAAATCAACCT), PB1-1105 d(AGCATGAAGCTCCGAA), PB1-1375 d(GTGAATG-CACCA), PB1-1600 d(GGAGTAACAGTG) PB1-1801 d(GATGGAGGACCAAACT), PB1-2046 d(CCTCAACA-CAAG), PB1-2209 d(GACTTCGAGTCTGGA), PA-158 d(GCTTCATGTATT), PA-226 d(CCAAATGCACTT), PA-452 d(CACACATCCACA), PA-681 d(CCCGCC-GAACTT), PA-876 d(GATGGATGCTTT), PA-1112 d(CGAGTCAGCTAA), PA-1339 d(GCAAGCATGAGA), PA-1540 d(AAAGGAAGATCTCA), PA-1601 d(CTCT-CACTGACC), PA-1789 d(CTCCAACAAATC), PA-1800 d(CGAGAGTATGAT), PA-1900 d(AAAGGAGTGGAA-GAA), PA-2009 d(CAAGAAAACTGC), PA-2026 d(GTC-GTTCAGGCT), PA-2080 d(CTATATGAAGCAATT), NP-160 d(TTCTACATCCAA), NP-202 d(GAGGGGGC-GACUG), NP-397 d(CGAATCTGGCGC), NP-643 d(GGGATCAATGAT), NP-888 d(TGGACCTGCCGT), NP-1015 d(CACAAGAGTCAG), NP-1285 d(GTGCAAA-GAAACCTTC), M-239 d(CGAGGACTGCAG), M-438 d(GCTGACTCCCAG), M-719 d(GATCTTCTTGAAAAT-TTG), M-895 d(GAGGGCCTTCTA), NS-207 d(G-

² Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Public Health Service or the Department of Health and Human Services.

GAAAGCAGATAGTG), NS-384 d(GACCAGGCAATC), NS-597 d(ACAGTTCGAGTC) and NS-742 d(GAAGT-GAGACAC). Primer numbers correspond to the position (in the mRNA sense sequence) of the first nucleotide in the primer.

Nucleotide sequence analysis of mRNA

The nucleotide sequence of the first 25-40 nucleotides of the 3' region of each gene was obtained using synthetic primers complementary to viral mRNA. Confluent MDCK cells were infected at a multiplicity of approximately 2 PFU/cell and harvested by scraping at 6 or 8 hr postinfection for the wt and mutant viruses, respectively. Cells were washed once in ice-cold phosphate-buffered saline and lysed in a buffer containing 5.8 M of guanidinium-hydrochloride, 50 mM of Tris-HCI (pH 7.6), 10 mM of EDTA, 2% sodium lauryl sarkosinate, and 1% β -mercaptoethanol prepared as described previously (Maniatis et al., 1982). RNA isolated by centrifugation through a CsCl cushion (Maniatis et al., 1982) was suspended in 20 mM Tris-HCI (pH 7.4), 1 mM EDTA and 0.1% sodium dodecyl sulfate (SDS), ethanol precipitated, and stored at -70° in sterile distilled water. Approximately 50 µg of total RNA was used in each incorporative sequencing reaction carried out as described above. Primers used were as follows: mNS-771 d(ATGGGGCATCACCTAGTT), mM-911 d(ACATCTTCAAGTCTCTGT), mNP-1433 d(CGACG-GATGCTCTGATTT), mPA-2151 d(GCTTTTTCAGCAA-GCTCGACAATC), mPB1-2233 d(GAGGATCTCCA-GTATAAG), and mPB2-2253 d(GTTAGTATCTCGC-GAGTG). Primer numbers correspond to the position (in the virion sense RNA sequence) of the first nucleotide in the primer.

Computer analysis

Nucleotide sequences were stored and manipulated on a Digital Equipment Corp. VAX computer using version 5 of the sequence analysis software package of the University of Wisconsin Genetics Computer Group (Devereaux *et al.*, 1984).

RESULTS

Nucleotide sequences of the NS1, NS2, M1, M2, NP, PA, PB1, and PB2 genes of the A/Ann Arbor/6/60 mutant and wt viruses were determined directly using the dideoxy chain termination method (Sanger *et al.*, 1977) modified for sequencing from virion RNA (Air, 1979). Bands in two lanes of the reaction were observed occasionally at a single nucleotide position. (These postions are indicated by asterisks in the figures). The darkest band was read as the correct nucle-

otide. In addition, the NS and M genes of the wt virus were cloned into pBR322 and sequenced using the chemical sequencing method of Maxam and Gilbert (1980). Results using the chemical method were identical to those using the dideoxy chain termination method (data not shown). The sequences of the HA and NA genes of the A/Ann Arbor/6/60 viruses were not determined because they are irrelevant for producing reassortant candidate vaccine strains. Sequences of H2N2 virus genes have been published previously for only the NS, NA, and HA genes. Therefore, each gene sequence of the wt A/Ann Arbor/6/60 virus was also compared with influenza A (H3N2) gene sequences available in the Gen Bank data base at the time of analysis.

NS1 and NS2 sequences

The smallest RNA segment of influenza virus is 890 nucleotides long and codes for the NS1 and NS2 polypeptides that are found only in infected cells (Inglis et al., 1979; Lamb and Choppin, 1979; Lamb et al., 1980). The functions of NS1 and NS2 are unknown. The complete nucleotide sequences for the NS genes of the A/ Ann Arbor/6/60 mutant and wt viruses are shown in Fig. 1. Two nucleotide differences were detected between the ca mutant and wt viruses with a coding change at nucleotide 483 in the portion of the gene that encodes NS1 and a noncoding change at nucleotide 813 in the portion of the gene that encodes NS2. The former nucleotide change encodes an alanine to threonine substitution in the mutant NS1 protein at amino acid 153. Comparison of the sequence we obtained for the A/Ann Arbor/6/60 wt NS gene with the sequence for this gene published previously (Buonagurio et al., 1986) revealed complete agreement, with only one additional change compared to the sequence of the A/ WSN/33 virus in a region not sequenced previously (T at nucleotide 35 in both ca and wt A/Ann Arbor/6/60 viruses). Volunteer studies with reassortant candidate vaccine strains having an RNA 8 from the H1N1 or H3N2 wild-type parent indicated that this gene is not required for attenuation (La Montagne et al., 1983). Studies with single gene reassortants are also consistent with the conclusion that RNA 8 does not contribute significantly to attenuation (Snyder et al., 1987).

M1 and M2 sequence

RNA segment 7 is 1027 nucleotides long and codes for at least two proteins, M1 and M2 (Allen *et al.*, 1980; Winter and Fields, 1980; Lamb *et al.*, 1981). The M1 protein is a viral structural protein of 252 amino acids. The M2 protein is 97 amino acids in length and, al-

				10							30	כ						5	D						70						9	90						1	10				
nt wt wt	AGC N-	CAA -te	IAA(arm:	GCF inu	IGGG Is N	TGF 51	anc	irga I NS	ICA 2	taa M	TGO	GRT D	P	raa N	CAC T	TGT V	GTC S	RAG S	CTT F	TCA Q	U U	AGF D	C	SCTI F	L	TTGG W	sca' H	TGT V	CCGI R	CAA K	ACAF Q	NGT V	TGCA A	iga D	CCA Q	aga E	ACT L	'AGI G	GTG D	ATC F	SCCI R I	CA	1T F(32)
at.			-	190							15	J						17	U						190						21	U						2	30				
wt	тсо	тт	GA	TCE	GCT	TCC	CCE	AGA	ITC	RGA	RG1	TCC	CTF	AG	GGG	ARG	AGG	CAG	TAC	тст	CGG	TCT	GRP	ICAT	CGA	RACF	IGCI	CRC	CCG.	TGT	TGGF	iaa	GCAG	AT	AGT	GGA	igag	GA.	TTC	TGF	hagi	JAF	iG
wt	L	-	D	R	L	R	R	ם	۵	ĸ	2	5	L	R	6	R	G	S	Т	L	6	L	N	I	Е	Т	A	т	R	V	6	ĸ	۵	I	Ų	Ε	R	I	L	k	< 1	Ξ	E(72)
mt.				250							270	כ						29	0						310						33	10						3	50				
mt					~~~	~~*	*~~																																				-
wt wt mt	HH	5	D	E	8	L	K	M	Т	M	F	900	S	A	P	R	S	R	Y	L	Т	D	M	Т	I	E	E	M	S	R	D	W	F	M	L	M	P	K	Q	HG I K	4444	, 16	iii R(112)
			3	970							390	כ						41	0						430						45	50						4	70				
mt wt wt	CRO	GC	CC1 P	TCT L	TTG C	TAT I	CAG R	iart M	GGA D	ACC Q	AGG F	SCF 9	ATC I	:Ati M	GGA D	таа К	IGAA N	CRTI	CATI	ATT L	GAA K	AGC R	:GAF N	ITT F	CAG S	TGTO	AT	TTT F	tga(D	CCG R	GCTF L	IGAI E	GACO	CTI L	AATI I	ATT L	ACT L	'AA/ R	GGGI A	CT7		1CC r	G E(152)
mt.			4	490							510)						59	D						550						57	0						5	90				
mt wt	RAG	1 GCG	GGA	RGC	AAT	TGT	TGG	CGA	IRR'	тт	CAC	CCF	тте	CC	ттс	тст	тсс	RGG	RCA'	TAC	TAA	TGF	IGGF	TGT	CAA	RAAT	rgci	RAT	TGGO	GGT	ссто	:RTI	CGGA	IGGI	ACT	TGP	ATG	GA	ATG	ATA	ance	-	G
ωt	F	1	G	A	I	Ŷ	G	Е	I	S	F	5	L	P	S	Ŀ	Р	G	Н	T	N	Ε	D	Ų	ĸ	N	A	I	G	Ų	L	I	G	G	L	E	W	N	D	1	1	ſ	V(192)
mt wt	I	-																D	I	L	. M	F		1 9	к	M	۵	L	G	s	s	s	Е	D	L	N	G	; 1	M	1	т	۵	(34)
mt			f	510						1	630	5						65	0						670						69	0						7	10				
πt															~~~														~~~~														_
wt wt	110	E B	V	S	K	T	L	нсн Q	R	F	F	9 9	W	R	5	S	D	E	N	G	R	P	P	L	Т	P	К	(21	БНН 7)	C	-ter	mi	sece nus	NS	ннсі 1	HHI	IHG	GI	CHHI	HHG	STTU	:GH	IR
mt wt	F	Е	s	L	к	L	Y	R)	s	L	G	Е	A	Ų	M	R	м	G	; D	L	. +	1 9	ιL	۵	N	R	N	G	к	М	R	Е	۵	L	. G	. 1	ו ב	к	F	Е	(74)
mt			-	720							750							77	n						700						01	•											
mt				130																					1 20							U	G					83	90				
ωt ωt mt	gaf E	IAT I	AAC R	SAT W	GGC L	TGA I	TTG E	aag E	AA6	STG / I	RGF R	ica H	icaa K	L	tga K	AGA I	TRA T	CAGI E	ng a i N	ATA S	GTT F	TTE E	RGC	CAAP	TAA T	CAT1 F	nta. M	TGCI	AAG(A	CCT L	TACF Q	IGC.	TRCT L	AT F	TTGI E	aag V	TGG E	AAC	CAAI I C	SAG E	i TAG	iAG R	iA (114)
			e	950						I	870	נ						890	כ																								
mt wt wt	rct T	ΤT F	сто S	GT F	TTC Q	RGC L	TTA	TTT (AR1 121	(GA)	TAF	RAA C-	lAAC ter	ACI mi	CCT nus	TGT NS	TTC 2	TRC'	Г																								

Fig. 1. Nucleotide and protein sequences of RNA segment 8 of the A/Ann/Arbor/6/60 wt and ca mutant viruses. Complete sequences are shown for the wt viruses. Nucleotide changes detected in the mutant RNA are shown above the wt sequence, while predicted amino acid changes in the mutant are shown below the wt sequence. Splice junctions for NS2 are indicated by arrowheads.

though its function is unknown, this protein is known to be inserted into plasma membranes of infected cells (Zebedee et al., 1985). Complete nucleotide sequence data for RNA 7 of A/Ann Arbor/6/60 ca mutant and wt viruses (Fig. 2) demonstrate that there was a single difference (G to T) at nucleotide 969. This nucleotide substitution encodes a change from alanine in the wt to serine in the mutant at amino acid 86 of the M2 protein. Comparison of the Ann Arbor/6/60 M2 sequences with those of other strains indicated that the M2 genes of the three other wt human strains sequenced to date have alanine at amino acid 86 of M2. This amino acid has been identified as one that varies between human and avian influenza strains (Buchler-White et al., 1986). Amino acid 86 is a part of the trypsin-sensitive carboxyterminal tail (Zebedee et al., 1985). One ca candidate vaccine strain, CR 31 Clone 3, that received the segment 7 from its wt parent in addition to the HA and NA genes (Cox et al., 1979) was attenuated in seronegative adult volunteers (La Montagne et al., 1983), but was less restricted in its replication in humans than a similar reassortant with segment 7 from the ca parent (Murphy et al., 1981). In addition, a reassortant with

only the genes encoding the PA, M1, and M2 proteins from the ca A/Ann Arbor/6/60 virus was as attenuated in human volunteers as another reassortant virus having all but the HA and NA genes from the ca donor virus (Snyder *et al.*, 1985). Further studies with single segment reassortant viruses also suggest that either the M1 or M2 proteins may play a role in attenuation (Snyder *et al.*, 1987). Sequence data presented here suggest that the M2 protein may be responsible for the observed biological findings.

NP sequence

The nucleoprotein gene [RNA segment 6 of the A/ Ann Arbor/6/60 viruses under electrophoretic conditions used to separate RNA (Cox *et al.*, 1985)] is 1565 nucleotides in length and encodes a basic structural protein of 498 amino acid residues that specifically interacts with RNA molecules to form ribonucleoprotein complexes (Winter and Fields, 1981; Huddelston and Brownlee, 1982) and has sequences that direct its migration into the nuclei of infected cells (Davey *et al.*, 1985). Three nucleotide changes were detected in the 558

COX ET AL.

at.			10						Э	0							50						7	0						90						11	10			
wt	AGC	AAA	AGCAG	GTR	GAT	8T1	GAA	RGF	ITGA	GTC	тт	стя	ACC	GA	GGT	CGA	RRC	, GTAI	CGT	тст	стс	TATI	сят	CCCI	STC	AGGO	CCC	ССТ	CAA	AGC	CGA	SAT	CGC	ACA	GAG	ACT	TGAR	AGAT	бто	тт
ωt	N	l-tei	rminu	us M	i a	nd	M2	1	1 5	L	. L	_	Т	Е	Ų	Е	Т	Y	Ų	L	S	I	I	Ρ	5	G	Р	L	к	Ĥ	Е	I	A	۵	R	F	Ε	D	Ŷ	F(32)
mt			100						10	~							70						10	0						210						.	20			
mt.			130						19	U						1	γU						12	U						610						<i>c</i>	90			
ωt	TGC	TGGI	GAAAA	ACA	CCG	ATC	TTG	AGG	стс	тся	TG	GRA	TGC	СТ	AAA	GRC	AAG	ACC	AAT	сст	GTC	ACC	тст	GAC	TAR	GGGI	SAT	ттт	GGG	ATT	TGTI	٩тт	CAC	GCT	CAC	CGTI	GCCI	CAGT	GAG	GCG
ωţ	R	G	κı	۹T	۵	L	. E	F	۹.L	M	I	E	М	L	κ	т	R	Ρ	I	L	S	Ρ	L	Т	к	G	I	L	G	F	Ų	F	т	L	T	V	Ρ	s	E	R(72)
mt			250							^						-	00						21	~						220						21	50			
nt.			200						27	u						2	90						31	u						330						3	90			
wt	AGG	RCT	GCAGI	CGTR	GAC	GC1	TTG	тсо	CAAA	ATG	CCI	стс	AAT	rggi	GAR	TGG	GGA	тсс	AAR	TAF	ICAT	GGA	CAG	AGC	AGT	TRA	ACT	GTA	TAG	AAA	GCT	TAA	IGAG	GGA	IGAT	AACI	RTTI	ССАТ	GGG	GC
ωt	G	L	Q	2 R	R	F	÷ (1	a N	f	i I	L	N	G	Ν	G	۵	Ρ	Ν	Ν	M	D	R	R	Ų	к	L	Y	R	к	L	κ	R	Ε	I	т	F	н	Ģ	R(112)
mt			770							~							10						43	n						450							70			
nt.			370						39	ų						4	τü						43							400							ſŬ			
ωt	CRF	AGA	AATAI	SCGC	TCF	GT	TTAT	ста	ств	GTG	CRI	стт	GCC	CAG	TTG	TRT	GGG	сст	САТ	ATF	ICAA	ICAG	GAT	GGG	GGC	TGT	GAC	CAC	TGA	IAGT	GGT	стт	AGG	ССТ	GGT	ATG	TGC	AACC	TG.	rga
ωt	κ	Е	ΙI	a L	. 9		1 9	i f	A G	F	1	L	A	S	C	Μ	G	L	I	Y	Ν	R	М	G	Ĥ	Ų	т	т	Е	Ų	Ų	L	G	L	Ų	С	R	т	С	E(152)
nt			400						51	n							20						55	.n						570						5	an			
mt			470						51	u							50						00							Jru							20			
wt	ACF	IGAT	TGCTI	GACT	CCC	:AG(CATE	IGG.	гстс	ATF	IGGI	CAR	IATO	GGT	GAC	AAC	AAC	CAR	тсс	ACT	raat	AAG	ACP	ITGA	GAA	CRG	AAT	GGT	TCT	GGC	CRG	CAC	TAC	AGC	TAR	IGGC	TAT	GGAG	SCAI	TAF
ωt	Q	I	RI	ם פ	5 6	1 1	I F	! !	5 H	R	5 1	۵	Μ	V	Т	Ŧ	Т	N	Р	L	I	R	Н	Ę	Ν	R	Μ	Ų	L	Ĥ	S	Т	Т	R	к	R	М	Е	۵	M(192)
mt			610						63	0						6	50						67	'n						con						7	10			
mt			010						03	ų.													01							0,00							10			
ωt	GGC	TGG	ATCGI	AGTE	RGC	RAN	SCAG	CRO	SAGG	CCF	ITG	GAG	GTI	TGC	TAG	TCF	IGGC	CAG	GCA	IRR1	GGT	GCA	GGC	RAT	GAG	AGT	TAT	TGG	GAC	TCA	TCC	TRO	CTC	CRG	STGC	TGG	тст	AAAF	ann.	Tga
ωt	A	G	5	5 E	: C		9 F		E A	۲	1	E	V	A	Ş	۵	8	R	Q	М	Ų,	Q	A	М	R	Ų	I	G	Ţ	н	Р	5	5	S	A	G	L	к	N	D(232)
			730						75	0						7	70						79	0						810						8	30			
мt							,																														_			
ωt	TCI	гтст	TGAA	RATT	төс	AG		RT	CAGA	RAC	GA	ATG	Gec	GGT	eca	GAT	GCA	ACG	RTT	CAF	IGTO	ACC	СТС	TTG	TTG	TTG	CCG	CGA	IGTF	ITCA	TTG	GGF	ITCT	TGC	ACT	TGA	TAT	TGTO	GA.	TTC
ωt.	L	L	E	NL			1 1	· I	a K		•	m	G	Υ.	ų	г	u	ĸ	F	ĸ	(20	2)		U-t	ern	inu	ST	11												
wt							Р	I	R	N	Ε	М	G	С	R		: N	0	Ś	: 9	5 0) P	L	. v	v	A	F	ìS	1	I	G	1	Ľ	. ト	1 L	. і	L	М	I	L(43)
πt																																								
			850						87	Ö						e	190						91	0						930						9	50			
nt.	ттс	יסדר	отот [.]	TTT3		000	тег	·oT	гтот	rer	ידדי	стт	то	or	one	сто	TCO	000	coc	eer	ירדז	сто	rec	000	coc	тог	roc	oct	отс	тео	cee	oor	דססי	orr	200	iocc	ممم	ocre	0.00	TC
มt	. [) H		F	F	ĸ	C	Ī	Y	R	F	F	K	unc H	ու։ G		. K	nnn P	G	F	5 5	i T	E	E G	U	P	Б	- G	. M	1 R	Ē	E	E Y	' E	20 K	E	опс 0	1965 0	non S	A(83)
лt			-				-	-	-		-	•			_				-		_		~			-					_	-						-	-	
			970						99	0						10	10																							
mt	CTO		T	TOOC		00		· . .	готе		·0 T	000	000		ост	000	000	<u>ото</u>	001	-			-																	
wit wit	L 1 E	טטוכ ו ו	- 19C	1 GAL	n D	S	H	F	0	nou S	T	F	10U I	F	716 I (9	117)	uninH C	uin ∽te	rni rni	101	: 11L : M2																			
et.	'		s	-	-	~	•••	•	•	-	-	-	-	-					,			•																		

Fig. 2. Nucleotide and protein sequences of RNA segment 7 of the A/Ann/Arbor/6/60 wt and ca mutant viruses. Complete sequences are shown for the wt viruses. Nucleotide changes detected in the mutant RNA are shown above the wt sequence, while predicted amino acid changes in the mutant are shown below the wt sequence. Splice junctions for M2 are indicated by arrowheads.

mutant NP gene sequence (Fig. 3) A change at nucleotide 113 encodes an amino acid substitution from threonine in the wt to asparagine in the ca mutant at amino acid 23, and a change at nucleotide 146 encodes an amino acid substitution from aspartic acid in the wt to glycine in the ca mutant at amino acid 34. The change at nucleotide 113 is not present in NP genes of other influenza viruses sequenced, while the change at nucleotide 146 is also present in the highly passaged laboratory strain, A/PR/8/34. The other change in the NP gene of the mutant is the insertion of a single A nucleotide in an A-rich region (1545-1550) that is near the putative polyadenylation signal (Robertson et al., 1981). This insertion may not be important because other influenza virion RNA segments have poly(U) tracts of varying lengths in corresponding positions. Although a ca NP gene was present in all the candidate vaccine strains we examined (Cox et al., 1986), no compelling genetic evidence exists to show that the NP genes of the ca mutant and wt A/Ann Arbor/6/60

viruses are associated with different phenotypic properties (Snyder *et al.*, 1987); therefore, the significance of the mutations in RNA 6 is unknown.

PA sequences

RNA segment 3 is 2233 nucleotides in length and encodes an acidic polymerase protein (PA) 716 amino acids in length (Fields and Winter, 1982; Bishop *et al.*, 1982b; Robertson *et al.*, 1984). The complete nucleotide sequences for the PA genes of A/Ann Arbor/6/60 mutant and wt viruses are presented in Fig. 4. Four nucleotide changes were detected in the mutant gene, with two of these changes located in the same codon. A change at nucleotide 20 (U to C) is in the noncoding region. Comparison of the A/Ann Arbor/6/60 sequences with published sequences revealed that A/ PR/8/34 and the Rostock strain of fowl plague virus have C at nucleotide 20 (Fields and Winter, 1982; Robertson *et al.*, 1984), while A/NT/60/68, like the A/Ann

			10					30					50					70					90				110	_	
nt ut ut	AG	scaa	AAGCA	GGGT	Agata	ATCA	ACTO	ACTGA	RGTGF	CATC	CAAAA	NTCA1	GGCC R	STCC(5 (CAAGI 2 G	SCACI T	CAAA(K I	CGGTC 2 S	ttri Y	igaac E C	CAGAT M	ggaf E	AACTGA T D	atgg(G	GGAAC E R	GCCAG Q	AATGC N R	R AACTGI T E N	I (25)
			130					150			•		170					190					210				230		
mt wt wt	ag R	AGC A	ATCCG S V	TCGG G	GARGA K 1	TGAT 1 I	itga D G	itggaf G 1	ATTGG I G	acga R	E Y	racat / I	CCAF	hatg: M (rgcai C T	CCGAI E	RCTTP L I	haact < L	CAG1 S	IGATI D 1	iatga ' E	GGGG G	R L	I I I	CCAGA Q N	IRCAGO I S	ttaac L T	AATAGI I E	R(65)
- +			250					270					290					310					330				350		
wt wt mt	at M	V V	GCTCT L S	CTGC A	F	ACGA	rgrig R	R N	nataf N K	ATAT Y	ICTGO L E	SAAGF E	ACA1 H	P 9	AGCGI 5 A	CGGGG G	GAAGO K [ATCC	taac K	K 1	ictge G	rggf G	PI	rata: Y	CAAGA K R	IGAGTA V	GATGG D G	AAAGT(K W	M(105)
-1			370					390					410					430					450				470		
wt wt	ag R	igga E	RCTCG L V	TCCT L	TTATO Y (GACAF) K	haga E	E 1	ataag I R	igcga R	I I I	igece N R	ICCAF Q	igctf R I	hatai 4 N	G G	TGAT(D (GATGC) A	racf T	AGCTO A G	GTCT G L	GRC1 T	icacat H M	IGATO M	SATCT I W	igecat I H	tccaa S N	tttgar L N	TGAT D(145)
~ +			490					510					530					550					570				590		
wt wt wt	AC T	raaci T	ATACC Y Q	agag R	GACAF T F	igago ? A	CTCT L		CGCAC R T	CGGA G	NATGO M C	ятсс) Р	R	atgi M (recti C S	L	SATGO M (CAGGG 1 G	TTCE S	FRCTO T L	тссс . Р	Tago R	R S	CTGGF G	AGCCG A A	icaggo I g	GCTGC A A	AGTCAR V K	AAGGA G(185)
			610					630					650					670					690				710		
mt wt wt	GT Ų	tgg G	Gricari T M	TGGT V	GATGO M E	agti E L	igat I	raagga R M	ATGAT 1 I	CAAA K	icgte R. e	GGAT GGAT	CAAT N	IGATO D F	CGGAA	ACTTI F	CTGGA W A	1GAGG ? G	TGAG E	AATO N G	GGCG R	GAAF K	ACAAG T R	igaat N	FGCTT R Y	ATGAG E	AGAAT R M	gtgcaf C N	I(225)
			730					750					770					790					810				830		
mt wt	ст	CAA	AGGAAI	AATT	TCAAF	CAGO	стес	ACAAF	AGAGO	AATG	ATGO	ATCF	AGTE	AGAG	SAAA	SCCGO	SAACO	CAGG	AAAT	IGCTO	AGAT	CGAF	IGATCT	САТС	CTTTC	TEECA	CGGTC	TGCACI	ICATA
wt.	L	к	GΚ	F	Q 1	. н	A	0 \$	5 A	M	MC	0	Ų	RE	E S	R	NF	, C	N	A E	1	Е	DL	I	FL	. A	RS	A L	I(265)
								070										~ ~ ~					000						
			850					870					890					910					930				950		
mt wt wt	TT L	'GAGI R	850 Aggeti G S	CAGT V	tgcto R H	RCAF	IATC S		CTGCC - P	TGCC A	TGTG C V	TGTF , Y	ITGGF G	ICCTO P f	SCCGT A V	ragci A	CAGTO S O	910 GCTA	CGAC	TTCE	aana K	AGAG E	930 GGATF G Y	ACTCI S	rttag L V	TAGGG G	950 ATAGA ID	CCCTTI P F	(CARA K(305)
mt wt wt	TT L	'GAGI R	eso Aggeti G S 970	CAGT V	tgcto R H	RCAF	ARTC S	870 TTGTC C L 990	ст <u>всс</u> - Р	TGCC A	TGTG C V	TGTF Y Y 1	UTGGF G 010	iccte P f	SCCG1 9 V	ragci A	CAGTO S O	910 GCTA GCTA GCTA	CGAC D	F E	AAAA K	AGAG E 1	930 GGATF G Y 1050	ICTCI S	rttag L V	TAGGG G	950 ATAGA I D 1070	P F	(CARA K(305)
mt wt wt mt	TT L CT	GAGI R GCT	eso Aggeti G S 970 TCAAAI	CAGT V RCAG	TGCTO R H	RCAF I K	ARTC S	870 TTGTC C L 990 CCTAF	CTGCC P	TGCC A	TGTG C V	TGTF V Y 1	UTGGF G 010 TCCF	ICCTO P F	SCCG1 1 V ACAF	ragco A RGAG1	CAGTO S O 1 1 1 1 1 1	910 GCTA GCTA GCTA COSO CTEGT	CGAC D GTGG	F E	iaana K	AGAG E 1 CAAT	930 GGATF 6 Y 1050 TTCTGC	ACTCI S	TTAG L V	TAGGG ' G AAGAT	950 ATAGA I D 1070 CTAAG	CCCTTI PF	ICARA K(305)
mtut nutut	TT L CT	GAGI R GCT	950 G S 970 TCAAAI Q N	Crigt V RCRG	TGCTC R F CCRAG Q L	RCAF I K TATF	ARTC S ACAG S	990 C L 990 CCTAF L I	CTGCC - P ATCAG	TGCC R ACCG P	:TGTG C V :RATG N E	itgtr Y 1 Iagar N	USO TEGEF G D10 TCCF P	iccte Pf IGCAC A F	iccgi V XACAF	ragci A Rgagi S	CRGTO S 0 1 CRGC 0 L	910 GCTA 030 .030 	CGAC D GTGG W	rtce F e Rtgg M F	iaana K Cate I C	RGAG E 1 CRAT N	930 6 Y 1050 TCTGC 5 R	ACTCI S TGCF A	ITTAG L V ATTTG F E	TAGGG G AAGAT D	950 ATAGA I D 1070 1070 CTAAG L R	CCCTTI PF AGTATO VS	icara K(305) XARGC S(345)
mttt tttt		GAGI R GCT L	850 RGGGTI G S 970 TCAARI Q N 1090	Crigt V RCRG S	TGCTC R H CCAAG Q L	RCAF I K TATF	ARTC S ACAG S	870 TTGTC C L 990 CCTAF L I 1110	tigec P TCRG R	rtgcc R R RCCG P	itgtg C V AATG N E	TGTA Y 1 RAGAA N 1	130 130 130	iccte Pf IGCAC R H	iccgi V XACAF	ragci A Raagi S	CAGTO SO 1 CAGO Q L 1	910 GCTR 030 TEGT 150	CGAC D GTGG W	rtce F e Atge M f	iaana K ICATG IC	AGAG E 1 CRAT N 1	930 66 7 050 TCTGC 5 R 170	ictci S TGCF A	ITTAG L V ATTTG F E	TAGGG G AAGAT D	950 ATAGA I D 1070 CTAAG L R 1190	CCCTTI PF AGTATO VS	rcaaa K(305) XAAGC S(345)
mwwm mwwm mww.		GAGI R GCT L CATO	850 RGGGTI G S 970 TCAAAI Q N 1090 CAGAGI R G	CAGT V RCAGI S GGACI	TGCTC R F CCAAG G V CAAAG K V	RCAF I K TATF Y TAAT	ARTC S ACAG S	990 CCTAF L I 1110 RAGGG	CTGCC - P ATCAG I R GGGAA	RCCG P ACTT L	TGTG C V AATG N E TCCA S T	TGTA Y 1 AGAA N 1 ICTAG R	130 TEGEF 010 TCCF P 130 AGGF	IGCAC P F IGCAC R F IGTAC V C	SCCG1 I V SACAF I K SAAA1 I I	ragco A RGAGI S rtgci A	CRGTO S 0 1 CRGC Q L 1 TCRF S N	910 66CTR 030 766TI 766TI 150 150 150	CGAC D GTGG W RAAC N	rtce F E Atee M F Rtee M C	iaana K I C I C	AGAG E 1 CAAT N 1 TATE M	930 6697F 6 Y 1050 7TCT&C 5 R 170 6697TC 6 S	ACTCI S TGCF A :AAGT S	TTTAG L V ATTTG F E TACTC T L	TAGGG G AAGAT D TTGAA E	950 ATAGA I D 1070 CTAAG L R 1190 CTGAG	CCCTTI PF RGTATO VS AAGCAG SR	ICAAA K(305) XAAGC S(345) SGTAC Y(385)
mwwm mwwm mwwm .	TT L CT L TT F	GAGI R GCT L CATI	850 REGETT G S 970 TCAAAI Q N 1090 CAGAGI R G 1210	Crigt V RCAGI S GGACI T	TGCTC A F CCAAG G L CAAAG K L	TATATI TATATI Y Y TAAT	ARTC S ACAG S FCCC P	870 TTGTC C L 990 CCTAF L I 1110 RAGGG R G	TGCC P TCRG R GGGAA	RCCG P	RATG RATG N E TCCA S T	TGTA Y AGAA N ICTAG R 1	890 TEGF 6 010 TCCF 9 130 AGGF 6 250	IGCAC P F IGCAC R F IGTAC V C	SCCGT IV CACAF IK CACAF I	ragca A Gaagi S TTGC1 A	CAGTO S O CAGO O L I TCAF S N	910 GCTA 030 TEGT 150 150 ATGA 1 E	CGAC D GTGG W RAAC N	RTGG M F RTGG M F	icatg i c i c	AGAG E 1 CAAT N 1 TATG M	930 6 7 .050 TTCT60 5 R .170 6 6 S .290	ACTCI S TGCF A S	TTTAG L V ATTTG F E FACTC T L	TAGGG G AAGAT D TTGAA E	950 ATAGA I D 1070 CTAAG L R 1190 CTGAG L R 1310	CCCTTI PF AGTATO VS AAGCAG SR	ICARA K(305) XARGC 5(345) GGTAC Y(385)
mwwm mwwm mwwm mw		GAGI R GCT L CATI I	850 REGETT G S 970 TCAAAI Q N 1090 CAGAGI R G 1210 CATAAG	CRGT V RCAG S S GGACI T	TGCTC R F CCAAG Q V CAAAG	RCAF I K TATF I Y TAAT	ARTC S ACAG S FCCC P	870 TTGTC C L 990 CCTAF L I 1110 RAGGG R G 1230 AAACF	CTGCC P ATCRG C R GGGAA GGGAA GGGAA	ACCG P ACTT L	C V C V AATG N E TCCA S T	TGTA Y 1 AGAA N 1 ICTAG R 1 IGGGC	TEGEF G 010 TCCFF P 130 AGGEF G 250 CTC1	IGCAC PF IGCAC RF IGTAC VC	RCRF RCRF K RCRF K RAAAT	ragco A Gaagi S TTGC1 A	CAGTO S 0 1 CAGC Q L 1 TTCAP S N 1 CAGTO	910 GCTA: 030 TEGT 150 150 ATEA 270	CGAC D GTGG W RAAAC N	RTGG M F RTGG M C	CATE CATE CATE	AGAG E 1 CAAT N 1 TATE M 1 TGTE	930 6687F 6 Y .050 TCT60 5 R .170 66870 6 S .290	TGCF S TGCF A S	TTTAG L V ATTTG F E TACTC T L	TAGGG G AAGAT D TTGAA E	950 ATAGA I D 1070 CTAAGI L R 1190 CTGAGI L R 1310	CCCTTI PF AGTATO VS AAGCAO SR	ICAAA K (305) XAAGC 5 (345) SGTAC Y (385)
mwwm mwwm mwwm mwwm		GRGI R GCT L CRT(I SGGC(A	850 RGGGTI G S 970 TCAAAI Q N 1090 CAGAGI R G 1210 CATAAI I R	Cragt V RCAGI S SGGACI T	TGCTC R F CCAAG G V CAGAAG R S	RCAF I K TATF I Y TAAT I I GTGG	ARTC S ACAG S FCCC P	870 TTGTC C L 990 CCTAF L I 1110 AAGGG R G 1230 AAACF N T	CTGCC - P ATCAG (R GGGAA S K ACTAA	ACCG P ACTT L	TCCA SAATO NE TCCA ST	ICTAG R ICTAG R IGGGC	890 TEGEF 6 010 TCCF P 130 AGGF 6 250 250 5	ICCTE Pf IGCAL R F IGTAL V C	SCCG V CACAA K CAAA1 V V SGTCA	ragci A Bgagi S TTGC1 A AAATI I	CRETE S CCREC C C C C C C C C C C C C C C C C C	910 GCTR 3 Y .030 TEGTI 150 150 INTGAI 1 E .270 TACAI 7 Q	CGAC D GTGG W RAACO N	ATGG M F ATGG M C TACGT	AAAAA K CATC I C ATAC I T S	right E 1 Crant N 1 Trate M 1 Trate V	930 6697F 6 Y .050 TTCTGC 5 R .170 6697C 6 S .290 608868 290 808886 80886 80886 80886 80886 80886 80886 80886 80886 80886 80886 8087 80 80 80 80 80 80 80 80 80 80 80 80 80	ACTCT S TGCF A S AAGT S	TTTAG L V ATTTG F E TACTC T L CCTCC	TAGGG G AAGAT D TTGAA E CATTT F	950 ATAGA I D 1070 CTAAG L R 1190 CTGAG L R 1310 GACAA 0 K	CCCTTT PF AGTATC V5 ARAGCAG SR ACCARC PT	(CARA K(305) CARGC S(345) GETAC Y(395) CCRTC I(425)
mwwm mwwm mwwm mwwm .		GRGI R GGCT L CATI I GGCCI A	850 AGGETT 6 S 970 TCAAAN 0 N 1090 CAGAGI R G 1210 CATAAN I R 1330	Crigt V RCRG S S GGRCI T S GGRCI T	TGCTC R F CCAAG Q V CAAAG K V CAGAAF R S	RCAF I K TATF Y TAAN I I GTGG G G	ARTC S ACAG S F CCCC P	870 TTGTC C L 990 CCTAF L I 1110 AAGGG R G 1230 AAACF N T 1350	CTGCC - P ATCAG I R GGGAA I R GGGAA I R ACTAA	rtgcc R Accg P Acctt L TCAR	TTCCA SAATG N E TTCCA S T ICAGA Q R	TGTAG P CAGAA CAGAA N N N N N N N N N N N N N N N N N N	890 TEGEF 6 010 TECEF P 130 REGEF 6 250 250 250 250	ICCTE P F IGCAC R F IGTAC V C	SCCG V CACAA K CAAAAT I I SGTCF G Q	ragci A Bgagi S TTGCI A Baati I	CAGTO S C I TCAGO CAGTO S N S CAGTO S N	910 GCTR: 030 TEGTI 150 150 150 150 150 150 150 150 150 150	CGAC D GTGG W RAAAC N RCCT P	rtce F E M F M F M C TACGT T F	CATE CATE I C TTTC	AGAG E 1 CAAT N 1 TATE M 1 TGTE V	930 6697F 6 Y 1050 TTCT60 5 R 170 6 S 1290 6088F0 8088F0 8088F0 8088F0 8088F0 8088F0 8088F0 8088F0 8088F0 8088F0 8088F0 8088F0 8088F0 8088 8087F0 8087F0 80 80 80 80 80 80 80 80 80 80 80 80 80	ictct S CTGCF A S CAAGT S SAAAC	TTTAG L V ATTTG F E TACTC T L CCTCC L P	TAGGG G AAGAT D TTGAA E CATTT F	950 ATAGA I D 1070 CTARG L R 1190 CTGAG L R 1310 GRCAR D K 1430	CCCTTI PF AGTATO VS AAAGCAG SR ACCAAG	CARA K(305) CARC 5(345) GETAC Y(385) CCATC I(425)
mwwm mwwm mwwm mwwm mwwm		GRAGI R GGCT L GGGCI A GGCCI A	eso Recetting 970 Crannin 1090 Crannin 1210 Crannin I R 1210 Crannin I R 1390 Recettin R	Crigt V RCRGI S GGGACI T TCRC T	TGCTC R H CCARRE Q L CRARRE K L CREAF R S TGEGGF G N	RCAF	ARTC S ACAG S F CCCC P SAGG G SAGG G	870 TTGTC C L 990 CCTAF L I 1110 RAGGE R E 1230 ARACF N T 1350 GGGAF G R	CTGCC - P ATCAG C R GGGAA C R ACTAA F N AGAAC 2 T	rtgcc R Accg P Acctt L Acctt CAR A Acct R CAR S	C V C V C AATG N E TCCA S T CAGA Q R CAGA Q R Q R Q M	stote 1 Sagaa N 1 Suctag R 1 Segec R 1 Suctag R 1 Suctag R 1 Suctag R 1 Suctag R 1 Suctag R 1 Suctag R 1 Suctag R 1 Suctag R 1 Suctag R 1 Suctag R 1 Suctag R 1 Suctag R 1 Suctag R 1 Suctag Su	890 TEGEF 6 010 TCCF P 130 AGGEF 6 250 250 250 250 370 6GCCF 8	IGCAC P F IGCAC R F IGTAC V C IGAAF E J	SCCGT A V CACAR A K CAAAA A I A I SGTCA A I CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	ragci Rgagt S TTGC1 R R RAATI R	CRISTING S ()) (CRISTING S ()) (CRISTING S ()) (CRISTING S ()) (CRISTING S ()) (CRISTING S ()))) (CRISTING S ())))) (CRISTING S ())))) (CRISTING S ())))) (CRISTING S ()))) (CRISTING S ()))) (CRISTING S ())))) (CRISTING S ()))) (CRISTING S ()))) (CRISTING S ()))) (CRISTING S ())))) (CRISTING S ()))) (CRISTING S ())))) (CRISTING S ()))) (CRISTING S ()))) (CRISTING S ()))) (CRISTING S ())))) (CRISTING S ()))) (CRISTING))) (CRISTING S ()))) (CRISTING S ())))) (CRISTING S ())))) (CRISTING S ())))) (CRISTING S ()))))) (CRISTING S ())))) (CRISTING S ())))) (CRISTING S ())))) (CRISTING S ())))) (CRISTING S ())))) (CRISTING S ())))) (CRISTING S ())))) (CRISTING S ()))))) (CRISTING S ()))))) (CRISTING S ()))))))) (CRISTING S ())))) (CRISTING S ()))))))))) (CRISTIN))))))))) (CRISTIN))))))) (CRISTIN)))))))))))))))))))	910 GECTR 3 Y 030 TTEGTI - V 150 ITEGTI 270 TTEGTI 1 E 390 ITEGTI 1 E	CGAC D GTGG W AAAAC N AAAAC N AAAAC P AGGGT G	CTTCC F E CATGG M F CATGG M C T T F CACGT T F CACGT T F CACGT R K	GCATG CATG CATG C CATAC C C C C C C C C C C C C C C C C	AGAG E 1 CAAT N 1 TATE M 1 TATE V 1 AGAAF E	930 666ATF 6 Y .050 TTCT60 5 A .170 6 S .290 606ATC 6 S .290 606AAA 8 .290 606AAA 8 .410 166AAGT E V	actor S CTGCF A S CAAGT S S CAAGT S S S S S S S S S S S	ITTAG L V ATTTG F E FACTC T L CCTCC L P CTTCC F Q	TTGAR D TTGAR E CATTT F AGGGG G	950 ATAGA I D 1070 CTAAGG L R 1190 CTGAGG L R 1310 GACAA D K 1430 CGGGGG R G	CCCTTT PF AGTATO VS ARAGCAR SR ACCARO PT AGTCTT VF	CRRA K(305) S(345) S(345) S(345) S(345) CRTC I(425) CCRTC I(425) CCRC E(465)
mwwm mwwm mwwm mwwm mwwm .		GAGI R GCT L GGCT I GGCT A GGCT A B GGCT A	850 AGGETT 970 TCAAAA 0 N 1090 CAGAAGE 1210 CAGAAGE 1210 CATAAA 1390 AGCATT R F 1450	Crigt V RCRGS S GGACI T SGGACI T TCAC T	TGCTC R H CCAAAG Q L CAAAAG K L CAAGAA R S CAAGAA R S TGGGGA G N	RCAF I K TATF I TAAT I I GTGG I G ATGC	artc S acag S rccc P sage G S acag S S acag S S C C C C C C C C C C C C C C C C C	870 TTGTC C L 990 CCTAF L I 1110 RAGGE R E 1230 ARAGE R 5 1230 ARAGE R 5 1230 CGEAA G K 1470	CTGCC - P ATCAG C R GGGAA AGGAAC AGGAAC 2 T	RTCAR A ACCG P ACTT L TCAR A ATCR S	CTGTG C V RAATG N E TTCCA S T ICAGAA Q R ICAGAA Q R ICAGAA Q R	TGTA Y 1 AGGAA N 1 ICTAG R 1 IGGGGC R 1 ITGAG I R 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	890 TEGEF 6 010 TCCF P 130 AGGF 6 250 CTC1 5 370 GGCF A 490	IGCAC P F IGCAC R F IGTAC V C IGAAF E J	GCCGT A V CACAA K CACAA A V CACAA A V CACAAA CACAAA CACAA CACAA CACAA CACAAAA CACAAA CACAAA CACAAA CACAAAAA CACAAA CACAAAA CACAAA CACAAAAA CACAAAAA CACAAAAA CACAAAA CACAAAA CACAAAAA CACAAA CACAAAAA CACAAAAA CACAAAA CACAAAA CACAAAA CACAAAA CACAAAAA CACAAAAA CACAAAAA CACAAA CACAAAAAA	ragci A Reag S TTGC1 A AAATI I RAGG R	CRGTE S CRGEC CRGTE S S CRGTE S CRGTE S CRGTE S CRGTE S 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	910 GGCTR 3 Y 030 CTGGTI 4 E 150 ITGGRI 4 E 390 17GGRI 510	CGAC D GTGG W RAAAC N RACCT P REGGT 6	CTTCC F E GATGG M F CATGG M C TACGT T F GCAF A K	GAAAAA CATG I C AATAC I T TTTC S AAACC I P	AGAG E 1 CAAT N 1 TATE M 1 TATE V 1 AGAF E 1	930 GEGATF G Y 050 TTCTGC 5 A 170 GEGATC 6 S 1290 GEGATC 6 S 1290 GEGATG 6 S 1290 GEGATG 6 S 1290 GEGATF 6 S 1290 120 120 120 120 120 120 120 12	ACTOT S CTGCF A CAAGT S CAAGT S CAAGT S CAAGT S	TTTAG L V ATTTG F E TACTC T L CCTCC L P CTTCC F Q	TREGE G AAAGAT D TTEAAA E CATTTT F AGEGEG G	950 RTAGA I D 1070 CTAAG L R 1190 CTGAG L R 1310 GACAA 0 K 1490 CGGGGG R G 1550	RECTATION P F RETATION V S RAGECARO S R RECCARO P T RECCARO V F	CRAA K(305) CRAC S(345) CCATC I(425) CCATC I(425) CCATC I(425)
. mwwm mwwm mwwm mwwm mwwm mwwm		GRGI R GCTT L GGCCI A GGCCI A CTCC S	eso Argestin G S 970 Crannin Carnani R G 1210 Crannan I R 1330 Crannan I R 1330 Crannan I R 1330 Crannan I R 1330 Crannan I R 1450 Seacerti C B	CRGT V RCAG S GGACI T TCAC T TCAC T	Tecto R F CCARE L CRARE K V CREAR R S CREAR R S GeCAR R T	RCAR I K TATIF I TATATI I I GTATI I GTATI I R A CGAA N	ARTC S ACAG S FCCC P SAGG G SAGG G SAGA E	870 C C L 990 CCTAF L I 1110 ARAGGE R G 1230 ARAGCF N T 1350 GGEGAA G K 1470 GATCG I V	CTGCC P ATCAG GGGAA GGGAA C R AGGAAC N AGGAAC N STGCCC P	RTCAR A RTCAR A RTCAR A RTCAR S CTCTT S	TTCCA STCCA STCCA ST CAGAGA Q R CAGAGA Q R CAGAGA C M TTTG F D	Stotf Y AGGAA N N CTAG R 1 CTAG R 1 TCAG N N CTAG N N N N	Teef 6 010 Tecr P 130 AGEF 6 250 CTC1 5 370 GECF A 490 S GRET 5	Incorte P F Incorte R Incorte In	SCCG 1 V CACAR 1 K CACAR 1 K CACAR 1 K CACAR 1 C CACAR 1 C CACAR 1 C C C C C C C C C C C C C C C C C C C	ragca A Agenen S TTGC1 A AnATC S ATC1 S	CAGTO S () TCAGO C L) TCAGO S N) CAGTO S N) SATGA S N) 1 CAGTO S N) 1 SATGA S N) 1 TTATT Y F	910 GECTR GECTR TGEGT TGEGT 150 150 150 150 150 150 150 150	CGAC D GTGG W RAAAC N RCCT P RGGT G	CTTCC F E CATGG M F CATGG M C T F CACGT T F C CACGT T F C CACGT T F C CACGT T F C CACGT T F C CACGT T F C C CACGT C C C C C C C C C C C C C C C C C C	GAAAAA CATG CATG C CATAC C CAACAC CAACAC CAACAC CAACACACAC	AGAGE E CAAT N 1 TATE M 1 TGTE V 1 AGAGE E 1 AGAGE	930 GGATF G Y 050 TTCTGC 5 A 170 GGATC 6 S 290 GCAAAC 0 R 410 GCAAAC 0 R 410 GGAAC 530 GGAAC 170 170 170 170 170 170 170 170	ACTO STOCF A SAAGT S SAAAG N S SAAAGT S S SAAAGT S S S S S ACGAC D	TTTAG L V ATTTG F E TACTC T L CTTCC CTTCC F Q CTTCC F Q CARTT N (4	TREGG G ARAGAT D TTGAA E CATTT F REGEGE G AREGEA 99)	950 ATAGA I D 1070 CTAAGG L R 1190 CTGAGG L R 1310 GACAA D K 1490 CGGGGG R G R G 1550 A AAAAA	CCCTTI P F AGTATI V S ARECRAC P T AGTCTI V F TACCCI	rcara K(305) SARGC S(345) SGTAC Y(395) CCATC I(425) CCATC I(425) CCARG E(465)

Fig. 3. Nucleotide and protein sequences of RNA segment 6 (NP) of the A/Ann/Arbor/6/60 wt and ca mutant viruses. Complete sequences are shown for the wt viruses. Nucleotide changes detected in the mutant RNA are shown above the wt sequence, while predicted amino acid changes in the mutant are shown below the wt sequence. The single nucleotide insertion is indicated by a 0 in the wt sequence at position 1550.

Arbor/6/60 wt, has U (Bishop *et al.*, 1982b). Thus it seems unlikely that this U to C change is important in attenuation. It is possible, however, that this change could alter base pairing of the ends of the RNA segment or polymerase recognition (Skehel and Hay, 1978; Robertson, 1979; Stoeckle *et al.*, 1987). A single base change in the noncoding region of the poliovirus 3 genome has been shown to affect attenuation (Evans *et al.*, 1985). A change from A to G at nucleotide 1861 encodes a lysine to glutamic acid substitution at amino acid 613. While this is a change from a basic to an acidic residue, it is not likely by itself to be involved in attenuation because comparison with other sequences revealed that A/PR/8/34, A/FPV/Rostock/34, and A/NT/60/68, like the A/Ann Arbor/6/60 mutant virus, all have glutamic acid at residue 613. The two other changes are in the same codon (TTA to CCA at nucleotides 2167 and 2168), resulting in a predicted amino acid substitution at residue 715 (the penultimate amino acid in the PA protein) from leucine in the wt to

	10	30	50	70	90	110
mt wt	L AGCGARAGCAGGTACTGATT	CGAAATGGAAGATTTTGTGC M E D F V R	GACAATGCTTCAATCCGATGA Q C F N P M I	ittetceaecttecteaa VELAEI	AAAGCAATGAARGAGTATGGAGI K A M K E Y G E	Aggatotgaaratogaaaca DLKIET(32)
mt.	130	150	170	190	210	230
wt wt	Arcarattigcagcaatatgi N K F A A I C	CACTCACTTGGAAGTATGCT T H L E V C F	TCATGTATTCAGATTTTCATT MYSDFHF	TCRTCARTGAGCAAGGCA INEQGI	GAGTCAATAATAGTAGAGCTTGI ESIIVELD	TGATCCAAATGCACTTTTG D P N A L L(72)
mt.	250	270	290	310	330	350
wt wt nt	ARGCACAGATTTGAARTAAT(K H R F E I I	igagggaagagatcgcacaa E G R D R T M	Tegcctegacagtagtagaaca R W T V V N S	IGTRTTTGCAACACTACA ICNTT	GGAGCTGAGAAACCGAAGTTTC G A E K P K F L	igccagatitigtatgattac PDLYDY(112)
nt	370	390	410	430	450	470
wt wt nt	RAGGAGARTAGRITICATOGAG K E N R F I E	SATTGGAGTGACAAGGAGGG IGVTRRE	ARGTCCACATATACTATCTTC VHIYYLE	arargeccrataratte K A N K I I	RAATCTGAGAAGACACACATCC KSEKTHIH	ICATITICTCATTCACTGGG IFSFTG(152)
nt	490	510	530	550	570	590
ωt ωt mt	CAAGAAATGGCCACAAAGGC(E E M A T K A	CGRCTACRCTCTCGATGAGG DYTLDEE	RARGCAGGGCTAGGATCAAAA S R A R I K T	RCCAGACTATTCACCATA	Agacaagaaatggctagcagag R D E M A S R G	L W D S F H(192)
nt	610	630	650	670	690	710
wt wt mt	CRGTCCGAAAGAGGGGGAAGAA Q S E R G E E	T I E E R F E	ARATCACAGGGACAATGCGCA ITGTMRR	IGGCTCGCCGACCAAAGT(L A D Q S L	CTCCCGCCGAACTTCTCCTGCC - P P N F S C L	rtgagarttttagagcctat E N F R A Y(232)
mt	730	750	770	790	810	830
wt wt mt	GTGGATGGATTCGAACCGAAC V D G F E P N	G Y I E G K L	S Q M S K E V	n a K I E F	CCTTTTCTGAAAACAACACCCAA PFLKTTPR	GACCAATTAGACTTCCGGAT PIRLPD(272)
mt	850	870 ×	890	910	930	950
ωt ωt mt	GEGECTICETIGTTCTCHGEGE	S K F L L M D	ALKLSIE	D P S H E C	GEAGAGAGGGAATACCACTATATGA E G I P L Y D	ATGCGATCAAGTGTATGAGA A I K C M R(312)
mt	970	990	1010	1030	1050	1070
ωt ωt mt	T F F G W K E	PYVVKPH	EKGINPN	HITHICIGCIGICHIGG Y L L'S W K	HIGCHAGTACTGGCAGAACTGCA COVLAELO	AGGACATTGAGAATGAGGAG DIENEE(352)
mt	1090	1110	1130	1150	1170	1190
wt wt mt	AAGATTCCAAGAACCAAAAAC KIPRTKN	:Atgaagaaaacgagtcagc: M K K T S Q L	TAAAGTGGGCACTTGGTGAGA KWALGEN	ACATEGCACCAGAGAAGE	STAGACTTTGACGACTGTAGAGA J D F D D C R D	TGTAAGCGATTTGAAGCAA V 5 D L K Q(392)
mt	1210	1230	1250	1270	1290	1310
wt wt mt	TATERTAGTERTERACCTERA Y D S D E P E	L R S L S S W	GGATCCAGAATGAGTTCAACA I Q N E F N K	AGGCATGCGAGCTGACCE	GRTTCAATCTGGATAGAGCTCGA DSIWIELD	itgagattggagaagatgtg E I G E D V(432)
nt	1330	1350	1370	1390	1410	1430
wt wt mt	GCTCCARTTGAACACATTGCA A P I E H I A	iagcatgagaaggaattact 5 M R R N Y F	TCACAGCAGAGGTGTCTCATT T A E V S H C	GCAGAGCCACAGAATATA RATEY]	TRATGARGGGGGTATACATTAR [M K G V Y I N	TACTGCCTTGCTTAATGCA TALLN A(472)
nt	1450	1470	1490	1510	1530	1550
ωt ωt mt	S C A A M D D	F Q L I P M I	TAAGCAAATGTAGAACTAAAG SKCRTKE	AGGGAAGGCGAAAGACCF G R R K T M	AATTTATRIGGTTICATCATAAA NLYGFIIK	Arggargateterenter G R S H L R(512)
πt	15/0	1590	1610	1630	1650	1670
wt wt mt		FVSMEFS	L T D P R L E	PHKWEK	HIGTHCTGTGTTCTTGHGHTAGG Y C V L E I G	D M L L R S(552)
mt	1020		1730	1730	1770	1790
ωτ ωt mt	A I G Q V S R	PMFLYVR	TNGTSKI	K M K W G M	1 E M R R C L L	
mt	1010		G			1910
ωt mt		S S V K E K D	M T K E F F K		PIGESPK	G V E E G S(632)
mt	ATTOCODOCTOTOCOCOCT	TTOTTOCCOOCTOCTOT				
ωt mt	I G K V C R T	L L A K S V F	N S L Y A S P	QLEGF9		
mt.	0000	COLO			2130	
ωc wt mt	R D N L E P G	TFDL66L	Y E A I E E C		IVLLNASW	F N S F L T(712)
mt			2210			
wt wt mt	P	unni6uiMuiMiii6UiMi[LUN I NU I S I UUMMMMMH I NU	UTTGET FUTHUI		

Fig. 4. Nucleotide and protein sequences of RNA segment 3 of the A/Ann/Arbor/6/60 wt and ca mutant viruses. Complete sequences are shown for the wt viruses. Nucleotide changes detected in the mutant RNA are shown above the wt sequence, while predicted amino acid changes in the mutant are shown below the wt sequence.

proline in the ca mutant. Although two nucleotide changes were found in the same codon, only a single nucleotide change from CCA to CTA is required for reversion back to leucine by the mutant. The other three influenza viruses sequenced to date have leucine at residue 715 of their PA proteins. The PA gene has been demonstrated to be involved in the cold-adaptation and attenuation properties of the mutant (Odagiri *et al.*, 1986; Snyder *et al.*, 1985, 1987), so this leucine to proline change may be relevant to virus phenotype.

PB1 sequence

RNA segment 2 is 2341 nucleotides in length and encodes a basic polymerase protein (PB1) 757 amino acids in length (Winter and Fields, 1982; Bishop et al., 1982a; Sivasubramanian and Nayak, 1982). Seven nucleotide differences were detected between the A/Ann Arbor/6/60 mutant and wt PB1 gene sequences (Fig. 5). Changes at nucleotides 123 and 486 were noncoding changes. Four coding changes were found at nucleotides 1195, 1395, 1766, and 2005 followed by a noncoding change at nucleotide 2019. The four coding changes result in amino acid substitutions of lysine to glutamic acid at amino acid 391, glutamic acid to aspartic acid at amino acid 457, glutamic acid to glycine at amino acid 581, and alanine to threonine at amino acid 661. None of these four changes exists in the three other wild-type PB1 genes sequenced to date, so any or all of them may be involved in the biological properties of the virus. Because RNA 2 of the mutant was absent in several ca reassortant vaccines that were fully attenuated (La Montagne et al., 1983), its role in attenuation has been questioned. Earlier genetic evidence (Cox et al., 1981) and more recent evidence using single gene reassortants in several animal models, however, suggest that mutations in RNA 2 may contribute to the temperature-sensitive and attenuation phenotypes of the ca A/Ann Arbor/6/60 virus (Snyder et al., 1987).

PB2 sequence

RNA segment 1 is 2341 nucleotides in length and encodes a basic polymerase polypeptide (PB2) of 759 amino acids (Fields and Winter, 1982; Kaptein and Nayak, 1982; Jones *et al.*, 1983; Roditi and Robertson, 1984). The complete nucleotide sequences of the A/ Ann Arbor/6/60 mutant and wt PB2 genes are shown in Fig. 6. Seven nucleotide differences were detected between mutant and wild-type sequences, at nucleotides 141, 426, 821, 1182, 1212, 1353, and 1923. Only the A to G change at nucleotide 821 encodes an amino acid change, from asparagine in the wt to serine in the mutant at amino acid 265. Examination of the other PB2 sequences available for other wt influenza A viruses revealed that asparagine is present at amino acid 265 in each case. However, a lower passage (E_3) A/Ann Arbor/6/60 wild-type virus sequenced in another laboratory, like the ca mutant, had serine at amino acid 265 (Herlocher, personal communication). The other six changes, A to G, U to C, A to U, C to U, U to G, and A to G at nucleotides 141, 426, 1182, 1212, 1353, and 1923, respectively, are all silent mutations within the coding region. All A/Ann Arbor/6/60 ca reassortant vaccines tested in clinical trials thus far (except single segment reassortants) derive their PB2 gene from the ca parent (Cox et al., 1986; Maassab, personal communication), and early genetic data indicated that RNA 1 may be involved in the temperature sensitivity of the mutant (Spring et al., 1977). More recent results using single segment reassortant viruses also indicate that RNA 1 contributes to the temperature-sensitive phenotype of the ca mutant (Snyder et al., 1987).

DISCUSSION

Here we describe the complete nucleotide sequences for the genes encoding the NS1, NS2, M1, M2, NP, PA, PB1, and PB2 proteins of the coldadapted and wild-type A/Ann Arbor/6/60 (H2N2) viruses. Few sequences are published for genes of H2N2 viruses. Such data are of evolutionary and epidemiologic significance because H2N2 viruses are proposed to be the immediate ancestors of the H3N2 subtype (Scholtissek et al., 1978; Nakajima et al., 1982). Comparisons between the wt A/Ann Arbor/6/60 gene sequences and those published previously for the H3N2 viruses A/NT/60/68 or A/Udorn/72 indicate that yearly rates of mutation of 0.36, 0.24, 0.28, 0.40, 0.68, and 0.49% occurred for the NS, M, NP, PA, PB1, and PB2 gene segments, respectively. These observations are consistent with the derivation of these genes in the H3N2 viruses from previously circulating H2N2 viruses.

We have identified 24 nucleotide differences between the A/Ann Arbor/6/60 ca mutant donor strain and its wt parent (Table 1). These 24 nucleotide changes constitute 0.2% of the total number of nucleotides sequenced. Our previous estimate (based on T_1 oligonucleotide mapping studies) that as many as 40– 60 nucleotide changes might have occurred in the total genome of the ca mutant (Cox *et al.*, 1986) was inaccurate. Comparison of deduced amino acid sequences for the parental and mutant viruses revealed 11 amino acid differences or 0.26% of the total number of amino acids (Table 1). Sequences for four other pairs of wt and attenuated viruses have been compared, and the

10 50 70 110 nt. RECERRAGE CRARECRATEGERATEGERETECCARECCETTACTTECTTECTEGRARETECCAREGERERATEGERETECCATEGERERATEG ٥t wt mt 5 H(32) 150 170 190 130 210 230 мt ut G T M D T Y N R T H Q Y S E K G K W T T N T E T G A H Q L N P(72) GT G Ð int 270 290 310 330 350 mt wt CTACI wt L P M E(112) пt 390 410 430 450 470 ΜΕ ΦΕ GTTATICARCARARCARGETGGRCARARCTGACCCARGECCTCCAGACCATTGGRCATTGGRCARTGAGCCGGCTGCGRCCTGCCCARGCCARACACCATATGAGGTCTTCAGATCG ΜΕΥΙΩΩΤ R V D K L T Ω G R Ω T Y D W T L N R N Ω P R R T R L R N T I E V F R S(1) P S(152) nt 490 510 530 550 R(192) nt 630 650 670 690 710 mt wt 8 F(292) ωt D ωt. 750 770 790 730 810 ABU WE REREGERRARTTARREAGERAGERGERARTECEAGERCECCEGETATECREAGERTCAGEGEGETETETETETEGERAGERGETATECEGERAGERTEGEGETTEGEGETTECEG WERGKLKRRAIATPGMILTRGFVYFVETLARSICEKLEQSGLV(2) P(272) 870 890 910 930 950 πt мс ul citiscregitratisararigaragetranctigecaratettetigegararateritateretraticaerargereterettettereratigeratererater ul v g g n e к к a к l a n v v r к м м t n s q d t e l s f t i t g d n t к w n e n:3 TITGDNTKWNEN(312) nt. 990 1010 1030 1050 1070 CRARATCCTCGGATGTTCCTGGCGATGATARCATACATCACARGARATCAACCTGAATGGTTTAGAAACGTCCTGAGCATCGCACCTATARTGTTCTCARATAAATGGCAAGACTAGGG G(352) N P R M F L A M I T Y I T R N Q P E W F R N V L, S I A P I M F ωt ۵ SNKMARL 1110 1130 1150 1170 1190 мŧ 1210 1230 1250 1270 1290 1310 πt мс ис повостотостантаратовося сабтотованостована то выбола то така и поволя по поволя по поволя по поволя по повол и LRPLLIDGTVSLSPGMMMGMF NMLSTVLGVSILNLGQKKYT(4 T(432) πt 1350 1370 1390 1410 1430 wt K L(472) пt D 1450 1470 1490 1510 1530 mt ωŧ 5 F(512) мt 1590 1610 1630 1650 1670 mt wt 1(552) wt G nt 1710 1690 1730 1750 1770 WE RAREACTACAGATATACGTACCGGTGCCACAGAGGAGAGAGACACACAAAATTCAGACAAGGAGATCATTCGAGCTAAAGGAGAGCTGTGGGAGCAAAACCCGGCTCAAAGGCAGGACTTTTGGTTTCG E Q T R S K A G L L G ыt. KDYRY YRCHRGDTQIQTRRSF ELKKLW 5(592) mt 1830 1850 1810 1870 1890 1910 πt GATGGAGGACCARACTTATACARATATCCGGAATCTCCACATTCCAGAAGTCTCCTCGAAGTGGCAGCACTAATGGAGAACATATCAGGGGAGGCTTTGTAATCCCCCGAATCCATTTGTC D G G P N L Y N I R N L H I P E V C L K W E L M D E D Y Q G R L C N P L N P F V(G V(632) мt 1930 1950 1970 1990 2010 2030 мt нетсятляясяяттсяетстваналантестветаятессяестсясеетссяессяяеяесятесяятятеятествстястястястяствсяетссствеятсссте ωtS H K E I E S V N N A V V M P A H G P A K S M E Y D A V Я Т TTHSWIP R(672) nt. 2070 2090 2110 2050 2130 2150 mt wt TCCRTTCTCRACACARAGCCARAGGGGARTTCTTGAAGATGAACAGATGTATCAGAAGGTGTTGCRATCTATTCGAGARATTCTTCCCTAGCAGTTCGTACAGGAGACCAGTTGGAATTTCC wt mt S Q R G I L E D E Q M Y Q K C C N L F E K F ILNT SSSYRRPVGIS(712) 2190 2210 2230 2250 2270 mt 2310 2330 те стоявловославалавтовтваттаествосствотсятовалаватесствоттотаст wt L R R 0 K(757)

FIG. 5. Nucleotide and protein sequences of RNA segment 2 of the A/Ann/Arbor/6/60 wt and ca mutant viruses. Complete sequences are shown for the wt viruses. Nucleotide changes detected in the mutant RNA are shown above the wt sequence, while predicted amino acid changes in the mutant are shown below the wt sequence.

110 90 10 . 50 70 ть ын поссялялосявотсяяттятяттсяятятабаялатяляларалствосорятсторатотсоссястсосоробатасталагарассяствоерессятатовоссяталтт ын. МЕРІКЕL РИL М SOS RT REILT КТТ V О Н МАІІ(Э1) ωt. шt 190 210 170 150 130 ۳t WE ARGAAGTACACATCAGGGAGAGAGAGAGAGAGAGAGGGCCCGTCACTTAGGATGAAATGAGTGGGATGAGAGTATCCGATTACAGCCGACAAGAGGGATAACAGAAATGATTCCTGAGAGAAAT WE K K Y T S G R Q E K N P S L R M K N M M A M K Y P I T A D K R I T E M I P E R N(7) E R N(71) nt 270 290 310 330 350 250 шт. WE GRECARGEGECARARCTCTATEGERETARARTEGAEGEARTEGEARTEGETETERTEGETETEGECARTEGARARTEGAECARTEGAECARTEGAECARATEGAECAR MEE Q G Q T L W S K M S D A G S D R V M V S P L A V T W W N R N G P M T S T V H Y (1 MTSTVHY(111) мt 430 C 450 410 390 mt. МЕ ССАВАВАЕТСТВОЕЛИСТ ТО ТО БОЛИВОЕТСАВАВСТОВАВСТ ТО ВОЛИВОЕТСЯ ТО ВОЛИВОЕТСЯ СТАТОВСКА СТАТОВСКА СТАВАЕТСА СТ G H(151) KIYKTYFEKVERLKHGTFGPVHFRNQVKIRRRVDINP wt P mt 590 550 570 510 530 490 mt. ωt gcagacctcrgtgccargegagecacageatgtaatctageaagtettettttccctaacgagegegegegeatgtaacctaacgaatcgcaattaaccaaaggaaaaaaagaa ωt a d l s a k e a Q d V I M e V V F P N e V g a R I L T s e s Q L T I T K e K K ε(1) K E K K E(191) mt 690 630 650 670 610 mt. πŧ 630 790 810 770 730 750 G R R A A(271) πt 890 910 990 870 ۳ŧ 1050 1010 1030 mt. WL ARRECTECRATEGEACTEREGATCRECTCATCCTTCRETTTTEECEGEGTTCACATTTAREAGRACARECEGATCATCAGTCAREAGRAGAGAGAGAGAGTCCTTACGGGCAATCTTCARACA WLK A A M G L R I S S S F S F G G F T F K R T S G S S V K R E E E V L T G N L Q T(351) mt 1150 1190 1170 1130 1090 1110 мt TMVGKRATAILRKATRRLIQLIVSGRDE(391) WELKIRVHEGYEEF мt 1290 1910 1270 1250 1210 1230 мt wEQSIREATIVAMVFSQEDCMIKAVRGDLNFVNRANDRLNPM(491) ۳t 1370 1390 1410 1350 яt G WE CRITCRACTITITAAGACATITITCAGAAGGATECTAAAGTSCTITITICAAAATTEGEGAATTGAACATATCGACAATGTGATGGATAATTSEEGTATTACCAGACATGATCCAAAGCACA 5 T(471) wth Q L L R H F Q K D A K V L F Q N H G I E H I D N V M G M I G V L P D M T P ont. 1510 1550 1450 1470 1490 1530 πt mt 1610 1650 1670 1570 1590 1630 WL CTACTATCTCCTGAGGAGGTCAGTGAAAACAGGGAACAGAGAAAACTGACGAATAACTTACTCATCGTCAATAGTGGGAGAATTAATGGCCCTGAGTGATGGTCAATAACCTATCAG wLLLSPEEVSETQGTEKLTITYSSSMMWWEINGPESVLVNTYQ(551) mt 1690 1710 1730 1750 1770 1790 πt TEGRICATCAGARARCTEGEGARARCTETTAGARATCCTAGARATCCTACARTECTATAGARATEGARTTTAGACCATTTCAGTCTTTAGTTCCTAGGCCATTAGAGGCCAA W I I R N W E T V K I Q W S Q N P T M L Y N K M E F E P F Q S L V P K A I R G Q(591) ωt nt 1850 1870 1890 1910 1810 1830 wŧ PKQSRM(691) SGFVR ыŧ Q Q M R D V L G T F D T T Q I I K L L P F A A A P T.L.F 1970 2010 1930 1950 1990 nt G SSLTVNVRGSGMRILVRGNSPIFNYNKTTKRLTILGKD(671) wt 0 F пt 2070 2090 2110 2130 2150 WE GCTGECACTTTRACTGARGACCCRARGTGARGECACATCTEGAGTGEGAGTCCCCCTTTCTGAGGAGATAGGAGAGATAGGAGATATGGACCAGCATTARGCATCAAT WE A G T L T E D P D E G T S G V E S A V L R G F L I L G K E D R R Y G P A L S I N(711) nt 2190 2230 2250 2170 2210 WL GAACTGAGTAACCTTECGAAAGEAGAAAAGGCTAATGGACAACTAATTGGCAAGCGTGGTGTTGGAAACGAAAAAGCGAAACTCTAGCAAAGCGAACAGCGAACAGCGAACC WLE L S N L A K 6 E K A N V L I G Q G D V V L V M K R K R N S S I L T D S Q T A T((751) πŧ 2310 ۳t ARAAGGATTCGGATGGCCATCAATTAATGTTGAATAGTTTAAAAACGACCTTGTTTCTACT WEKRIRMAIN(759)

Fig. 6. Nucleotide and protein sequences of RNA segment 1 of the A/Ann/Arbor/6/60 wt and ca mutant viruses. Complete sequences are shown for the wt viruses. Nucleotide changes detected in the mutant RNA are shown above the wt sequence, while predicted amino acid changes in the mutant are shown below the wt sequence.

TABLE 1	
---------	--

SUMMARY OF COMPARATIVE SEQUENCE DATA FOR A/ANN Arbor/6/60 WILD-TYPE AND MUTANT VIRUSES

5114		Nucleot	ide change	Position cha	anged	Amino acid c	change
RNA segment	No. of changes	wt	MT	Nucleotide	a.a.	wt	MT
1 (PB2)	1 Coding change	AAC	AGC	821	265	Asn	Ser
. ,	4 Noncoding changes	AGA	AGG	141		·	
	0 0	GTI	GTC	426		_	
		АТ <u>А</u>	ATI	1182			
		GC <u>C</u>	GCI	1212			
		GCI	GC <u>G</u>	1353	_		
		CA <u>A</u>	CA <u>G</u>	1923			
2 (PB1)	4 Coding changes	AAA	GAA	1195	391	Lvs	Glu
- ()		GAG	GAI	1395	457	Glu	Asp
		GAG	GGG	1766	581	Glu	Glv
		<u>G</u> CT	ACT	2005	661	Ala	Thr
	3 Noncoding changes	GG <u>A</u>	GG <u>G</u>	123			_
	-	GG <u>C</u>	GG <u>T</u>	486		— .	-
		TC <u>C</u>	TCI	2019	—	<u> </u>	
3 (PA)	2 Coding changes	AAG	GAG	1861	613	Lys	Glu
	5 5	ΠA		2167-8	715	Leu	Pro
	1 Noncoding change	I	Ç	20	—	Noncoding	
Region							
6 (NP)	2 Coding changes	ACT	AAT	113	23	Thr	Asn
. ,	0 0	G <u>A</u> T	GGT	146	34	Asp	Gly
	Single nucleotide insertion	GAAAAAT	GAAAAA <u>A</u> T	1550	—	Noncoding	
Region 7 (M1)		_		_			
(M2)	1 Coding change	<u>G</u> CT	ICT	969	86	Ala	Ser
8 (NS1)	1 Coding change	GCG	ACG	483	153	Ala	Thr
(NS2)	1 Noncoding change	CTA	CTG	813	_	_	

total number of nucleotide or amino acid changes acquired during attenuation represents less than 1% of the genome or protein in each case (reviewed by Cohen et al., 1987). There are more differences between wt and ca A/Ann/Arbor/6/60 viruses than between wt and vaccine strains of poliovirus 3 but fewer differences than between wt and vaccine strains of poliovirus 1, yellow fever virus, hepatitis A virus HM-175 (Cohen et al., 1987), and influenza B viruses (DeBorde et al., 1988). It seems clear that relatively few changes are present in a variety of attenuated RNA viruses. Because viral RNA genomes are extremely heterogeneous (Domingo et al., 1985), sequencing of a viral RNA template results in a consensus sequence consisting of the base present at the greatest frequency at each nucleotide position. Sequence variations present in minor subpopulations remain undetected. These low frequency sequence variations, however, would not be expected to contribute significantly to the phenotypic properties of the virus.

During the many clinical studies conducted with investigational cavaccines derived from the ca A/Ann Ar-

bor/6/60 virus, over 900 isolates from human volunteers have been tested for the phenotypic properties of cold-adaptation and temperature-sensitivity, and no true revertants have been detected (Murphy et al., 1980; Wright et al., 1982; Maassab, personal communication). Similarly, reversion has not been demonstrated in ferrets (Maassab et al., 1982). This is in contrast to results with investigational ts influenza live attenuated vaccines (Murphy et al., 1980; Tolpin et al., 1981). It is likely, therefore, that more than one of the mutations identified here are biologically important, so that if reversion or suppression of one mutation occurs, attenuation conferred by other independent mutation(s) remains. This is supported by data obtained with single gene reassortants (Snyder et al., 1987). Thus, all available data support the previous suggestion that candidate vaccine strains be selected on the basis of having six internal genes of the mutant donor parent since multiple mutations throughout the genome might confer increased stability (Cox et al., 1979, 1986).

Now that the precise nature of the mutations in the A/Ann Arbor/6/60 ca donor strain has been deter-

mined, it would be relatively simple to sequence rapidly the relevant areas of each gene in viruses prepared for human use or in viruses recovered from infected volunteers to monitor the stability of these mutations during production and use of ca reassortant candidate vaccines. This approach would not detect suppressor mutations (Scholtissek, 1984), however, and monitoring of phenotypic properties would also be important.

Because it would be expected that a combination of nonspecific mutations and mutations specific for the phenotypic properties of the ca A/Ann Arbor/6/60 virus might occur during the process of cold-adaptation, we have attempted to deduce the likelihood that the mutations detected are involved in the phenotypic properties of the virus. After taking into consideration the available data, we suggest that the changes in the ca A/Ann Arbor/6/60 virus that are of particular interest for future study are as follows: (1) the alanine to serine change at amino acid 86 in the M2 protein, (2) the leucine to proline change at amino acid 715 in the PA protein, (3) the asparagine to serine change at amino acid 265 in PB2, and (4) any or all of the four changes in the PB1 protein. While it is useful to attempt to identify those changes most likely to be involved in the phenotypic properties of the ca virus, conclusions made at this time must be viewed as preliminary for the following reasons: (1) Some contradictions appear in results from genetic complementation or recombination experiments that used different ts mutant sets (Spring et al., 1977; Reeve et al., 1980a; Cox et al., 1981). (2) Conclusions about the genetic basis of attenuation made with single segment reassortants may not apply for different wild-type parents. (3) Mixing polymerase genes of two human influenza viruses may in itself attenuate a reassortant (Florent, 1980). (4) Some of the mutations in the A/Ann Arbor/6/60 ca mutant that are also present in other wt sequences may be biologically significant in the context of other sequence changes. Experiments that use site-specific mutagenesis and DNA expression systems to demonstrate the effect of a particular mutation in a functional assay as well as experiments to obtain and sequence phenotypic revertants will be necessary to further define the biological importance of the mutations reported here. Until definitive studies are complete, it is advisable that, to minimize the risk of reversion to virulence, vaccines used in open populations contain all genes except those coding for HA and NA from the caparent.

ACKNOWLEDGMENTS

We thank Ms. Judith Galphin for expert technical assistance and Ms. Denise Johnson for manuscript preparation. We also thank Louise Herlocher for providing prepublication sequences of RNA 1 of the A/Ann Arbor/6/60 ca and wt viruses.

REFERENCES

- AIR, G. M. (1979). Nucleotide sequence coding for the "signal peptide" and N-terminus of the hemagglutinin from an Asian (H2N2) strain of influenza virus. *Virology* **97**, 468–472.
- ALLEN, H., MCCAULEY, J., WATERFIELD, M., and GETHING, M. J. (1980). Influenza virus RNA segment 7 has the coding capacity for two polypetides. *Virology* **107**, 548–551.
- BELSHE, R. B., and VAN VORIS, L. P. (1984). Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: Infectivity and efficacy against investigational challenge. J. Infect. Dis. 149, 735–740.
- BISHOP, D. H. L., HUDDELSTON, J. A., and BROWNLEE, G. G. (1982a). The complete nucleotide sequence of RNA segment 2 of influenza A/NT/60/68 and its encoded P1 protein. *Nucleic Acids Res.* **10**, 1335–1343.
- BISHOP, D. H. L., JONES, K. L., HUDDELSTON, J. A., and BROWNLEE G. G. (1982b). Influenza A virus evolution: Complete sequences of influenza A/NT/60/68 RNA segment 3 and its predicted acidic p polypeptide compared with those of influenza A/PR/8/34. *Virology* 120, 481–489.
- BUCHLER-WHITE, A., NAEVE, C. W., and MURPHY, B. R. (1986). Characterization of a gene coding for M proteins which is involved in hostrange restriction of an avian influenza virus in monkeys. J. Virol. 57, 697–700.
- BUONAGURIO, D. A., NAKADA, S., PARVIN, J. D., KRYSTAL, M., PALESE, P., and FITCH, W. M. (1986). Evolution of human influenza A viruses over 50 years: Rapid, uniform rate of change in NS gene. *Science* 232, 980–982.
- CATE, T. R., and COUCH, R. B. (1982). Live influenza A/Victoria/75 (H3N2) virus vaccines: Reactogenicity, immunogenicity and protection against wild-type virus challenge. *Infect. Immun.* 38, 141– 146.
- CLEMENTS, M. L., O'DONNELL, S., LEVINE, M. M., CHANOCK, R. M., and MURPHY, B. R. (1983). Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: Role of local antibody in resistance to infection with vaccine virus. *Infect. Immun.* 40, 1044–1051.
- COHEN, J. I., ROSENBLUM, B., TICEHURST, J. R., DAEMER, R., FEINSTONE, S., and PURCELL, R. H. Comparison of the nucleotide sequence of wild-type hepatitis A virus and its attenuated candidate vaccine derivative. (1987). *In* "Modern Approaches to New Vaccines" (R. M. Chanock, R. A. Lerner, F. Brown, and H. Ginsberg, Eds.), pp. 327–331. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- COUCH, R. B., QUARLES, J. M., CATE, T. R., and ZAHRADNIK, J. M. (1986). Clinical trials with live cold-reassortant influenza virus vaccines. *In* "Options for the Control of Influenza" (A. P. Kendal and P. A. Patriarca, Eds.), pp. 223–241. A. R. Liss, New York.
- Cox, N. J. (1986). Progress and limitations in understanding the genetic basis for attenuation of live attenuated influenza vaccines. *In* "Options for the Control of Influenza" (A. P. Kendal and P. Patriarca, Eds.), pp. 207–221. A. R. Liss, New York.
- Cox, N. J., and KENDAL, A. P. (1984). Genetic stability of A/Ann Arbor/ 6/60 cold-mutant (temperature-sensitive) live influenza virus genes: Analysis by oligonucleotide mapping of recombinant vaccine strains before and after replication in volunteers. J. Infect. Dis. 149, 194–200.
- COX, N. J., KENDAL, A. P., MAASSAB, H. F., SCHOLTISSEK, C., and SPRING, S. B. (1981). Genetic synergism between matrix protein and polymerase protein required for temperature sensitivity of the cold-adapted influenza A/Ann Arbor/6/60 mutant virus. *In* "The Replication of Negative Strand Viruses" (D. H. L. Bishop and R. W. Compans, Eds.), pp. 405–413. Elsevier North Holland, New York.

- COX, N. J., KENDAL, A. P., SHILOV, A. A., ALEXANDROVA, G. I., GHENDON, Y. Z., and KLIMOV, A. I. (1985). Comparative studies of A/Leningrad/134/57 wild-type and 47-times passaged cold-adapted mutant influenza viruses: Oligonucleotide mapping and RNA/RNA hybridization studies. J. Gen. Virol. 66, 1697–1707.
- Cox, N. J., KITAME, F., KLIMOV, A., KOENNECKE, I., and KENDAL, A. P. (1986). Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza virus: Detection of mutations in all genes of the A/Ann Arbor/6/60 (H2N2) mutant vaccine donor strain. *Microbiol. Pathogen.* **1**, 387–397.
- Cox, N. J., MAASSAB, H. F., and KENDAL, A. P. (1979). Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza viruses: Nonrandom reassortment of genes during preparation of live vaccine candidates by recombination at 25° between recent H3N2 and H1N1 epidemic strains and cold-adapted A/Ann Arbor/6/60. *Virology* 97, 190–194.
- DAVENPORT, F. M., HENNESSY, A. V., MAASSAB, H. F., MINUSE, E., CLARK, L. C., ABRAMS, G. D., and MITCHELL, J. R. (1977). Pilot studies on recombinant cold-adapted live type A and B influenza virus vaccines. *J. Infect. Dis.* **136**, 17–25.
- DAVEY, J., DIMMOCK, N. J., and COLMAN, A. (1985). Identification of the sequence responsible for nuclear accumulation of the influenza virus nucleoprotein in *Xenopus* oocytes. *Cell* **40**, 667–675.
- DEBORDE, D. C., DONABEDIAN, A. M., HERLOCHER, M. L., NAEVE, C. W., and MAASSAB, H. F. (1988). Sequence comparison of wildtype and cold-adapted B/Ann Arbor/1/66 influenza virus genes. *Virology* **163**, 429–443.
- DEBORDE, D. C., NAEVE, C. W., HERLOCHER, M. L., and MAASSAB, H. F. (1986). Resolution of a common RNA sequencing ambiguity by terminal deoxynucleotidyl transferase. *Anal. Biochem.* **157**, 275–282.
- DEVEREAUX, J., HAEBERLI, P., and SMITHIES, O. (1984). A comprehensive set of sequence analysis programs for the VAX. *Nucleic Acids Res.* 12, 387–395.
- DOMINGO, E., MARTINEZ-SALAS, E., SOBRINO, F., DE LA TORRE, J. C., PORTELA, A., ORTIN, J., LOPEZ-GALINDEZ, C., PEREZ-BRENA, P., VILLA-NUEVA, N., NAJERA, R., VANDE POL, S., STEINHAUER, D., DE POLO, N., and HOLLAND, J. (1985). The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: Biological relevance—A review. *Gene* 40, 1–8.
- EVANS, D. M. A., GUNN, D., MINOR, P. D., SCHILD, G. C., CANN, A. J., STANWAY, G., ALMOND, J. W., CURREY, K., and MAIZEL, J. V., JR. (1985). Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. *Nature (London)* **314**, 548–550.
- FIELDS, S., and WINTER, G. (1982). Nucleotide sequences of influenza virus segments 1 and 3 reveal mosaic structure of a small viral RNA segment. *Cell* **28**, 303–323.
- FLORENT, G. (1980). Gene constellation of live influenza A vaccines: brief report. Arch. Virol. 64, 171–173.
- HRABAR, A. I., VODOPIJA, I., ANDRE, F. E., MITCHELL, J. R., MAASSAB, H. F., HENNESSY, V., and DAVENPORT, F. M. (1977). A placebo-controlled dose-response study of the reactogenicity and immunogenicity of a cold-adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers. *Dev. Biol. Stand.* **39**, 53–60.
- HUDDLESTON, J., and BROWNLEE, G. G. (1982). The sequence of the nucleoprotein gene of human influenza A virus, strain A/NT/60/68. *Nucleic Acids Res.* **10**, 1029–1038.
- INGLIS, S. C., BARRETT, T., BROWN, C. M., and ALMOND, J. W. (1979). The smallest genome RNA segment of influenza virus contains two genes that may overlap. *Proc. Natl. Acad. Sci. USA* 76, 3790– 3794.
- JONES, K. L., HUDDLESTON, J. A., and BROWNLEE, G. G. (1983). The

sequence of RNA segment 1 of influenza virus A/NT/60/68 and its comparison with the corresponding segment of strains A/PR/8/34 and A/WSN/33. *Nucleic Acids Res.* **11**, 1555–1566.

- KAPTEIN, J. S., and NAYAK, D. P. (1982). Complete nucleotide sequence of the polymerase 3 gene of human influenza virus A/WSN/ 33. J. Virol. 42, 55–63.
- KENDAL, A. P., MAASSAB, H. F., ALEXANDROVA, G. I., and GHENDON, Y. Z. (1981). Development of cold-adapted recombinant live, attenuated influenza A vaccines in the U.S.A. and U.S.S.R. *Antiviral Res.* 1, 339–365.
- LAMB, R. A., and CHOPPIN, P. W. (1979). Segment 8 of the influenza virus genome is unique in coding for two polypeptides. *Proc. Natl. Acad. Sci. USA* **76**, 4908–4912.
- LAMB, R. A., CHOPPIN, P. W., CHANOCK, R. M., and LAI, C-J. (1980). Mapping of the two overlapping genes for polypeptides NS1 and NS2 on RNA segment 8 of the influenza virus genome. *Proc. Natl. Acad. Sci. USA* 77, 1857–1861.
- LAMB, R. A., LAI, C-J., and CHOPPIN, P. W. (1981). Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: Colinear and interrupted mRNAs code for overlapping proteins. *Proc. Natl. Acad. Sci. USA* **78**, 4170–4174.
- LA MONTAGNE, J. R., WRIGHT, P. F., CLEMENTS, M. L., MAASSAB, H. F., and MURPHY, B. R. (1983). Prospects for live, attenuated influenza vaccines using reassortants derived from the A/Ann Arbor/6/60 (H2N2) cold-adapted (ca) donor virus. *In* "The Origin of Pandemic Influenza Viruses" (W. G. Laver, Ed.), pp. 243–257. Elsevier, New York.
- LAZAR A., OKABE, N., and WRIGHT, P. F. (1980). Humoral and cellular immune responses of seronegative children vaccinated with a cold-adapted influenza A/HK/123/77 (H1N1) recombinant virus. *Infect. Immun.* 27, 862–866.
- MAASSAB, H. F. (1967). Adaption and growth characteristics of influenza virus at 25°C. Nature (London) 213, 612–614.
- MAASAB H. F., KENDAL A. P., ABRAMS G. D., and MONTO A. S. (1982). Evaluation of cold-recombinant influenza virus vaccine in ferrets. *J. Infect. Dis.* **146**, 780–790.
- MAASSAB, H. F., KENDAL, A. P., and DAVENPORT, F. M. (1972). Hybrid formation of influenza virus at 25°C. *Proc. Soc. Exp. Biol. Med.* 139, 768–773.
- MANIATIS, T., FRITSCH, E. F., and SAMBROOK, J. (1982). "Molecular Cloning: A Laboratory Manual," pp. 189–196. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- MAXAM, A. M., and GILBERT, W. (1980). Sequencing end-labeled DNA with base-specific chemical cleavages. *In* "Methods in Enzymology" (L. Grossman and K. Moldave, Eds.), Vol. 65, pp. 497–559. Academic Press, New York.
- MORITZ, A. J., KUNZ, C., HOFMAN, H., LEIHL, E., REEVE, P., and MAAS-SAB, H. F. (1980). Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus II: Evaluation in adult volunteers. *J. Infect. Dis.* **142**, 857–860.
- MURPHY, B. R., CHANOCK, R. M., CLEMENTS, M. L., ANTHONY, W. C., SEAR, A. J., CISNEROS, L. A., RENNELS, M. B., MILLER, E. H., BLACK, R. E., LEVINE, M. M., BETTS, R. F., DOUGLAS, R. G., JR., MAASSAB, H. F., COX, N. J., and KENDAL, A. P. (1981). Evaluation of A/Alaska/ 6/77 (H3N2) cold-adapted recombinant viruses from A/Ann Arbor/ 6/60 cold-adapted donor virus in adult seronegative volunteers. *Infect. Immun.* **32**, 693–697.
- MURPHY, B. R., HOLLEY, H. P., JR., BERQUIST, E. J., LEVINE, M. M., SPRING, S. B., MAASSAB, H. F., KENDAL, A. P., and CHANOCK, R. M. (1979). Cold-adapted variants of influenza A virus: Evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the coldadapted A/Ann Arbor/6/60 strain. *Infect. Immun.* 23, 235–259.

- MURPHY, B. R., NELSON, D. L., WRIGHT, P. F., TIERNEY, E. L., PHELAN, M. A., and CHANOCK, R. M. (1982). Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. *Infect. Immun.* **36**, 1102–1108.
- MURPHY, B. R., RENNELS, M. B., DOUGLAS, R. G., BETTS, R. F., JR., CHA-NOCK, R. M., KENDAL, A. P., MAASSAB, H. F., SUWANAGOOL, S., SOT-MAN, S. B., CISNEROS, L. A., ANTHONY, W. C., NALIN, D. R., and LE-VINE, M. M. (1980). Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. *Infect. Immun.* 29, 348–355.
- MURPHY, B. R., TOLPIN, M. D., MASSICOT, J. G., KIM, H. Y., PARROTT, R. H., and CHANOCK, R. M. (1980). Escape of a highly defective influenza A virus mutant from its temperature sensitive phenotype by extragenic suppression and other types of mutation. *Ann. N.Y. Acad. Sci.* **354**, 172–182.
- NakaJima, K., NakaJima, S., and Sugiura, A. (1982). The possible origin of H3N2 influenza virus. *Virology* **120**, 504–509.
- ODAGIRI, T., TOSAKA, A., ISHIDA, N., and MAASSAB, H. F. (1986). Biological characteristics of a cold-adapted influenza A virus mutation residing on a polymerase gene. *Arch. Virol.* **88**, 91–104.
- PALESE, P., and SCHULMAN, J. C. (1976). Difference in RNA patterns of influenza A virus. J. Virol. 17, 876–884.
- REEVE, P. G., ALMOND, J. W., FELSENREICH, V., PIBERMAN, M., and MAASSAB, H. F. (1980a). Studies with cold-recombinant A/Victoria/ 3/75 (H3N2) virus. I. Biologic, genetic, and biochemical characterization. J. Infect. Dis. 142, 850–856.
- REEVE, P. G., BATIA, G., MORITZ, A., LIEHL, E., KUNZ, C., HOFMAN, H., and MAASSAB, H. F. (1980b). Studies in man with cold-recombinant influenza virus (H1N1) live vaccines. *J. Med. Virol.* **6**, 75–83.
- ROBERTSON, J. S. (1979). 5' and 3' terminal nucleotide sequences of the RNA genome segments of influenza virus. *Nucleic Acids Res.* 6, 3745–3757.
- ROBERTSON, J., ROBERTSON, M., and RODITI, I. (1984). Nucleotide sequence of RNA segment 3 of the avian influenza A/FPV/Rostock/ 34 and its comparison with the corresponding segment of human strains A/PR/8/34 and A/NT/60/68. *Virus Res.* 1, 73–79.
- ROBERTSON, J., SCHUBERT, M., and LAZZARINI, R. A. (1981). Polyadenylation sites for influenza virus mRNA. J. Virol. 38, 157–163.
- RODITI, I., and ROBERTSON, J. (1984). Nucleotide sequence of the avian influenza virus A/Fowl Plague/Rostock/34 Segment 1 encoding the PB2 polypeptide. *Virus Res.* **1**, 65–71.
- SANGER, F., NICKLEN, S., and COULSON, A. R. (1977). DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* 74, 5463–5467.
- SCHOLTISSEK, C. (1984). Temperature-sensitive (ts) mutants of an influenza A virus for which genetic synergism is required to express the ts phenotypes. *Virus Res.* 1, 677–685.
- SCHOLTISSEK, C., RHODE, W., and VON HOYNIGEN, V. (1978). On the origin of human influenza subtypes H2N2 and H3N2. *Virology* **87**, 13–20.

- SIVASUBRAMANIAN, N., and NAYAK, D. P. (1982). Sequence analysis of the polymerase 1 gene and the secondary structure prediction of polymerase 1 protein of human influenza virus A/WSN/33. *J. Virol.* 44, 321–329.
- SKEHEL, J. J., and HAY, A. J. (1978). Nucleotide sequences at the 5' termini of influenza virus RNAs and their transcripts. *Nucleic Acids Res.* 5, 1207–1219.
- SNYDER, M. H., BETTS, R. F., DEBORDE, D., TIERNEY, E. L., CLEMENTS, M. L., HERRINGTON, D., SEARS, S. D., DOLIN, R., MAASSAB, H. F., and MURPHY, B. R. (1987). Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) coldadapted reassortant virus vaccines. J. Virol. 62, 488–495.
- SNYDER, M. H., CLEMENTS, M. L., DEBORDE, D., MAASSAB, H. F., and MURPHY, B. R. (1985). Attenuation of wild-type human influenza A virus by acquisition of the PA polymerase and matrix protein genes of influenza A/Ann Arbor/6/60 cold-adapted donor virus. J. Clin. Microbiol. 22, 719–727.
- SPRING, S. B., MAASSAB, H. F., KENDAL, A. P., MURPHY, B. R., and CHA-NOCK, R. M. (1977). Cold-adapted variants of influenza A. II. Comparison of the genetic and biological properties of ts mutants and recombinants of the cold-adapted A/AA/6/60 strain. *Arch. Virol.* 55, 233–246.
- STOECKLE, M. Y., SHAW, M. W., and CHOPPIN, P. W. (1987). Segmentspecific and common nucleotide sequences in the noncoding regions of influenza B virus genome RNAs. *Proc. Natl. Acad. Sci.* USA 84, 2703–2707.
- STUART-HARRIS, C. (1980). The present status of live influenza virus vaccine. J. Infect. Dis. 142, 784–793.
- TOLPIN, M. D., MASSICOT, J. G., MULLINIX, M.G., KIM, H. W., PARROTT, M. D., CHANOCK, R. M., and MURPHY, R. B. (1981). Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant *in vivo. Virology* **112**, 505–517.
- VAN VOORTHUIZEN, F., JENS, D., and SAES, F. (1981). Characterization and clinical evaluation of live influenza A vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and cold-adapted A/ Ann Arbor/6/60 (H2N2) strains. *Antiviral Res.* 1, 107–122.
- WINTER, G., and FIELDS, S. (1980). Cloning of influenza cDNA into M13: The sequence of the RNA segment encoding the A/PR/8/34 matrix protein. *Nucleic Acids Res.* 8, 1965–1974.
- WINTER, G., and FIELDS, S. (1981). The structure of the gene encoding the nucleoprotein of human influenza virus A/PR/8/34. *Virology* 114, 423–428.
- WINTER, G., and FIELDS, S. (1982). Nucleotide sequence of human influenza A/PR/8/34 segment 2. *Nucleic Acids Res.* **10**, 2135–2143.
- WRIGHT, P. F., OKABE, N., MCKEE, K. I., MAASSAB, H. F., and KARZON, D. T. (1982). Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J. Infect. Dis. 146, 71–79.
- ZEBEDEE, S. L., RICHARDSON, C. D., and LAMB, R. A. (1985). Characterization of the influenza virus M_2 integral membrane protein and expression at the infected-cell surface from cloned cDNA. *J. Virol.* **56**, 502–511.